



**Effectiveness of continence promotion for older women via community organisations: a cluster randomised trial**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004135
Article Type:	Research
Date Submitted by the Author:	27-Sep-2013
Complete List of Authors:	Tannenbaum, Cara; Université de Montréal, Faculty of Medicine Agnew, Rona; Glasgow Caledonian University, Benedetti, Andrea; McGill University, Departments of Medicine and of Epidemiology, Biostatistics & Occupational Health Thomas, Doneal; McGill University, Departments of Medicine and of Epidemiology, Biostatistics & Occupational Health van den Heuvel, Eleanor; Brunel University,
<b>Primary Subject Heading</b>:	Urology
Secondary Subject Heading:	Geriatric medicine
Keywords:	Urinary incontinences < UROLOGY, PUBLIC HEALTH, GERIATRIC MEDICINE

SCHOLARONE™  
Manuscripts

Effectiveness of continence promotion for older women via community organisations:  
a cluster randomised trial

Cara Tannenbaum, MD, MSc<sup>1</sup> Rona Agnew, PhD<sup>2</sup> Andrea Benedetti, PhD<sup>3</sup> Doneal  
Thomas, MSc<sup>4</sup> Eleanor van den Heuvel, PhD<sup>5</sup>

<sup>1</sup>Associate Professor, Faculty of Medicine, Université de Montréal, Quebec, Canada

<sup>2</sup>Clinical Research Fellow, Glasgow Caledonian University, Glasgow, UK

<sup>3</sup>Associate Professor, Departments of Medicine and of Epidemiology, Biostatistics &  
Occupational Health, McGill University, Quebec, Canada

<sup>4</sup>PhD candidate, Department of Epidemiology, Biostatistics & Occupational Health,  
McGill University, Quebec, Canada

<sup>5</sup>Director of Assistive Technology Programme, Brunel Institute for Ageing Studies,  
Brunel University, Uxbridge, UK

Word count : 3182

Key words: Continence promotion, cluster trial, community organisations, older  
women, urinary incontinence

Corresponding Author: Dr. Cara Tannenbaum, Centre de Recherche de l'Institut  
universitaire de gériatrie de Montréal, 4545 Queen Mary Road, Montreal, Quebec,  
Canada H3W 1W5. Tel (514) 340-2800. Fax : (514) 340-3530.

Email: [cara.tannenbaum@umontreal.ca](mailto:cara.tannenbaum@umontreal.ca)

The Corresponding Author has the right to grant on behalf of all authors and does  
grant on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ  
Publishing Group Ltd to permit this article (if accepted) to be published in BMJ Open  
editions and any other BMJ PGL products and sublicences such use and exploit all  
subsidiary rights, as set out in the licence.

1  
2  
3 All authors have completed the Unified Competing Interest form at  
4 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding  
5 author) and declare: no support from any organisation for the submitted work; no  
6 financial relationships with any organisations that might have an interest in the  
7 submitted work in the previous three years, and no other relationships or activities that  
8 could appear to have influenced the submitted work.  
9  
10  
11  
12

13  
14 The authors retained full independence from the study sponsors in the design,  
15 implementation, analysis, interpretation and reporting of the findings.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objectives:** The primary objective of this cluster randomised controlled trial was to compare the effectiveness of the three experimental continence promotion interventions against a control intervention on urinary symptom improvement in older women with untreated incontinence recruited from community organisations. A second objective was to determine whether changes in incontinence-related knowledge, new uptake of risk-modifying behaviours explained these improvements.

**Setting:** 71 community organisations across the United Kingdom

**Participants:** 259 women aged 60 years with untreated incontinence entered the trial; 88% completed the 3-month follow-up.

**Interventions:** The three active interventions consisted of a single 60-minute group workshop on 1) continence education (20 clusters, 64 women); 2) evidence-based self-management (17 clusters, 70 women); or 3) combined education and self-management (17 clusters, 61 women). The control intervention was a single 60-minute educational group workshop on memory loss, polypharmacy and osteoporosis (17 clusters, 64 women).

**Primary and secondary outcome measures:** The primary outcome was self-reported improvement in incontinence 3 months post-intervention at the level of the individual. Changes in incontinence-related knowledge and behaviours were also assessed.

**Results:** The highest rate of urinary symptom improvement occurred in the combined intervention group (66% vs 11% of the control group, prevalence difference 55%, 95% CI 43%-67%, intraclass correlation 0). Thirty percent versus 6% of participants reported significant improvement respectively (prevalence difference 23%, 95% CI 10%-36%, intraclass correlation 0). The number-needed-to-treat was 2 to achieve any improvement in incontinence symptoms, and 5 to attain significant improvement. Changes in knowledge and self-reported risk-reduction behaviours paralleled rates of improvement in all intervention arms.

1  
2  
3 **Conclusion:** Continence education combined with evidence-based self-management  
4 improves symptoms of incontinence among untreated older women. Community  
5 organisations represent an untapped vector for delivering effective continence  
6 promotion interventions.  
7  
8  
9

10  
11 **Trial registration:** ClinicalTrials.gov ID number NCT01239836  
12  
13

14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

### Article Summary : Strengths and limitations of this study

- First study to provide Level 1 evidence that continence promotion is an effective strategy for improving urinary symptoms among untreated community-dwelling older women
- Participants were recruited via community organisations with representation across diverse socio-economic strata
- Rates of knowledge acquisition and behaviour change provide an explanatory mechanism for the observed improvements in incontinence in participants receiving the education combined with the self-management strategy
- Only self-reported outcomes and crude dichotomous measures of behaviour change were collected so results must be interpreted with caution

## Introduction

Urinary incontinence is more frequent than breast cancer, heart disease or diabetes among older women, but remains a stigmatized and untreated condition despite its high prevalence. [1-4] In the United States, Canada, the U.K. and other European countries, up to 40% of women aged 65 years and older experience involuntary urine leakage, but little more than 15-30% seek care.[1-4] Even fewer physicians feel competent evaluating or treating incontinence.[5-6] Urinary incontinence is associated with obesity, cardiovascular disease, diabetes, depression, social isolation, decline in function, falls, nursing home admission, and onerous out-of-pocket expenses.[6-10] In many cases incontinence can be improved, and even cured, when evidence-based diagnostic and treatment strategies are appropriately applied.[6,11-14]

It is a commonly held misconception that incontinence is a normal part of aging.[15] Not-for-profit organisations seek to raise continence awareness worldwide and promote treatment for incontinent individuals. Media campaigns, brochures and public awareness lectures attempt to de-stigmatise incontinence and increase help-seeking, but the effectiveness of these initiatives for reaching their target population remains unknown.[15] Transmission of public health education via community organisations is an unexplored strategy for improving urinary symptoms.[16] Data from randomised trials are needed to determine whether the delivery of an evidence-based, continence intervention via community organisations is an effective method for treating incontinence.

The primary objective of this cluster randomised controlled trial was to compare the effectiveness of the three experimental continence promotion interventions against a control intervention on urinary symptom improvement in older women with untreated incontinence recruited from community organisations. A second objective was to determine whether changes in incontinence-related knowledge, attitudes and new uptake of risk-modifying behaviours explained improvements in incontinence. We hypothesized that continence education combined with evidence-based self-management would yield the greatest improvement in incontinence symptoms, measured at the level of the individual, 3-months post-intervention.

## METHODS

### Study design and oversight

A 4 arm, parallel-group, controlled, cluster randomised trial was conducted. The study design, recruitment methods and interventions have been reported.[16] Clustering was at the level of the community organisation, from whence participants were recruited. The choice of a cluster design served to prevent contamination between participants in the same community organisation. The trial was designed by two of the authors and was overseen by the full investigator team, which had full access to the data. The data were collected at community organisations across the United Kingdom. All participants provided written informed consent. The protocol was approved by the Brunel University Research Ethics Committee.

### Study population and recruitment

Inclusion criteria for community organisations included any organisation throughout the United Kingdom that consented to participate in the trial between November 2010 and September 2012. A community organisation was loosely defined as any not-for-profit group of individuals with a shared interest. These included interest and charity groups, seniors' housing groups, women's lobby groups and Asian caregiver associations.[16] Organisations were contacted strategically by convenience sampling, word of mouth and referral. A research coordinator approached community organisations to join the trial by telephone, email and newspaper advertising.

Inclusion criteria for participants were women aged 60 years and older who reported urinary incontinence at least once weekly on the International Consultation on Incontinence Questionnaire (ICIQ), and who were not under active treatment for incontinence. For privacy reasons, many community organisations were uncomfortable screening their members for incontinence in advance, so eligibility to participate in the trial could only be ascertained by the research coordinator on the day of delivery of the intervention.[16] Eligibility to participate in the trial was established by asking all attendees at the workshop to complete a baseline screening questionnaire upon arrival. At this time, a study information sheet and consent form were distributed to all participants. All women, regardless of eligibility or desire to enrol in



1  
2  
3 the trial, were permitted to stay for the workshop. Only those women who wished to  
4 enrol in the trial submitted the signed consent form to the workshop facilitator  
5 following delivery of the intervention, however all attendees were encouraged to  
6 submit the baseline screening questionnaire even if they were continent or did not  
7 want to participate in the trial.  
8  
9  
10

### 11 12 13 **Interventions**

14  
15  
16 The interventions were applied at the level of each cluster. The three experimental  
17 interventions to be tested were continence education, self-management including the  
18 distribution of an evidence-based risk factor reduction tool for incontinence, and a  
19 combined intervention that included both components. The sham control intervention  
20 was a lecture on health promotion for older women that addressed topics other than  
21 incontinence. All interventions were delivered once in group format to 8-16 women  
22 by the same facilitator at a venue of the organisation's choosing, and lasted 60-90  
23 minutes. A slide presentation with a pre-established script prepared for the facilitator  
24 was delivered at each workshop.  
25  
26  
27  
28  
29  
30  
31

32  
33 The continence promotion intervention incorporated elements of constructivist  
34 learning that challenged older adults' erroneous beliefs about accepting incontinence  
35 as a normal part of aging, and aimed to change attitudes and create new knowledge  
36 about the different types, etiology, risk factors and treatment options for urine  
37 loss.[16-17] The self-management workshop reviewed self-management theory in an  
38 interactive format, and provided a customised evidence-based self-management  
39 program for risk factor modification for incontinence to each participant.[18-19] The  
40 program targeted pelvic floor muscle weakness, obesity, consumption of caffeinated  
41 beverages, smoking, vision loss and constipation, with instructions on how to keep a  
42 bladder diary to help monitor symptoms. The content of the combined intervention  
43 condensed elements from the continence promotion workshop along with self-  
44 management theory, and provided the customized self-management tool to  
45 participants. The control intervention addressed other non-bladder related aspects of  
46 older women's health such as memory problems, polypharmacy, osteoporosis,  
47 nutrition, physical fitness and vision impairment.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Study Outcomes

The primary outcome was the participant's global impression of improvement in incontinence symptoms, measured at 3 months post-intervention by telephone interview using the patient's global impression of improvement (PGI-I) questionnaire. The PGI-I is a validated, single-item global rating of change scale that asks the patient to describe how their incontinence condition is now compared to how it was prior to the intervention (very much better, much better, a little bit better, no change, a little bit worse, much worse and very much worse).[20] The primary outcome, any improvement, was defined as a rating of a little bit better, much better or very much better. A secondary outcome, significant improvement, was defined as much better or very much better. The ICIQ, which measures the frequency, severity and bother from incontinence was used at baseline to screen participants for inclusion to the trial, and was repeated at follow-up.[21] The ICIQ diagnostic item was used by participants to describe the type of incontinence at baseline. A pre- and post-8-item questionnaire on knowledge and attitudes towards incontinence was administered at baseline and at 3-month follow-up, as were risk factors and behaviors related to incontinence.[17] Risk factors and behaviors included performance of pelvic floor muscle exercises three times weekly (yes, no), daily consumption of 1 cup or more of tea or coffee (yes, no), fluid intake > 1.5 L/day (yes, no), weight and height (self-report) and smoking status (yes, no). At three month follow-up participants were asked whether they had sought treatment for urine leakage during the past 3 months. All follow-up interviews were performed by the research coordinator, who was blinded to participant identification.

### Randomisation and allocation concealment

Group allocation occurred by non-stratified randomisation in blocked groups of 4 of consenting organisations that agreed to host a workshop. An independent statistician at a distant study site was responsible for randomisation using computer-generated random digits. Community organisations were informed that one of four workshops would be delivered on health topics of interest to older women, but not which one. In this way, group allocation was concealed from both the clusters and the individual participants, who were invited by the host organisation to attend a "Women's Health Workshop". The research coordinator remained unaware of group allocation at the

1  
2  
3 time each community organisation was recruited to the trial because she was only  
4 informed which workshop to prepare for each organisation several days before each  
5 workshop. The trial is considered open-label because both the research facilitator who  
6 delivered the intervention and the participants who received it were aware of which  
7 intervention was being delivered.  
8  
9  
10

### 11 12 13 **Sample Size**

14 The trial was designed to detect a minimal 35% difference in the number of  
15 participants reporting any improvement (very much better, much better, a little bit  
16 better on the PGI-I) between the experimental and control conditions, assuming a rate  
17 of improvement in the control condition as high as 20%, with 80% power and alpha  
18 0.05 two-sided (n=34). Using an inflation factor of 1.65 to account for an anticipated  
19 maximum intracluster correlation (ICC) of 0.05 and unequal cluster size yielded a  
20 recruitment target of 56 participants per group.[22]  
21  
22  
23  
24  
25  
26  
27

### 28 **Statistical Methods**

29 Differences in baseline characteristics between the four groups were determined. To  
30 assess the primary outcome we estimated the unadjusted risk difference (prevalence  
31 of the outcome) and 95% confidence intervals (CI) via generalized estimating  
32 equations (GEEs) for participants who reported any improvement on the PGI-I. We  
33 repeated the same analysis for those who reported significant improvement. GEEs  
34 with an identity link and an exchangeable correlation structure were used to account  
35 for possible correlation between women in the same organisation.[23] To adjust for  
36 the imbalance in potential confounders in the groups at baseline, additional analyses  
37 were conducted using multivariable logistic regression estimated via GEE with an  
38 exchangeable correlation structure. Potential confounders included age and baseline  
39 incontinence severity (ICIQ score) as continuous predictors, and living alone,  
40 depression, heart disease, falls, arthritis, diabetes, high blood pressure, educational  
41 status and general health perception as dichotomous predictors. Both intent-to-treat  
42 (ITT) and per protocol (PP) analyses were performed. For the ITT analysis,  
43 participants with missing data were assumed to have no change in incontinence status  
44 at three-month follow-up. The number needed to treat was calculated as the inverse of  
45 the difference in absolute event rates between the experimental and control  
46 groups.[24] We report intra-cluster (intra-community organisation) correlation  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 coefficients (ICC) from the marginal model using GEE with assumed exchangeable  
4 correlation structure and robust standard errors.[25] To estimate adjusted mean group  
5 differences in ICIQ scores from baseline to 3-month follow up, we used GEE with a  
6 Gaussian regression model for continuous outcomes and followed the same procedure  
7 outlined above.  
8  
9

10  
11  
12 Improvements in incontinence-related knowledge by intervention type for proportions  
13 of individuals responding correctly to each knowledge questionnaire item at baseline  
14 compared to 3-month follow-up were estimated using McNemar's test for matched  
15 pair analysis. Rates of improvement in self-reported risk modifying behaviours for  
16 incontinence were calculated, along with 95% confidence intervals. Differences in  
17 improvement rates between the intervention and the control group were compared  
18 using Fisher's Exact test using a per protocol analysis. A difference in response for  
19 each health behavior item that indicated adoption of a new risk modifying behaviour  
20 was defined as a positive change at 3-month follow-up compared to baseline.  
21  
22

23  
24 Reduced coffee and tea intake refer to individuals who reduced their consumption to a  
25 single cup per day or less. Weight loss was determined by a positive response to the  
26 question, "Has your weight changed (yes, no) and if so, how much do you now  
27 weigh?" and evidence of self-reported current weight lower than self-reported weight  
28 at baseline. All statistical analyses were run using RStudio 0.97.310.0, an integrated  
29 development environment for R.  
30  
31  
32  
33  
34  
35  
36  
37  
38

## 39 RESULTS

### 40 Study participants and follow-up

41  
42  
43 Four-hundred-and-twenty different community organisations were approached over  
44 an 18-month period to participate in the trial. Of these, 17% consented and succeeded  
45 in hosting an intervention, yielding 71 clusters that were randomised. Approximately  
46 one quarter of the groups contacted refused; 2% expressed interest but were unable to  
47 organise a workshop; and a little over half failed to give any response although most  
48 of them had been followed up and had received extra information on the project.<sup>16</sup>  
49  
50 Figure 1 depicts the study flow of the clusters and participants through the trial.  
51  
52 Seven-hundred-and-sixty three women attended the workshops, of whom 322 (42%)  
53 were known to be eligible for the trial. The mean number of participants recruited  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 from each cluster for the continence promotion group was  $3 \pm 2$ , whereas it was  $4 \pm 2$   
4 for the other 3 groups. Eighty-percent (259/322) of known eligible attendees to the  
5 workshops consented to take part in the trial. Two-hundred-and-twenty-eight of these  
6 (88%) were available for 3-month follow-up. Table 1 compares the baseline  
7 characteristics of participants in each trial arm.  
8  
9  
10

### 11 **Primary outcomes**

12 The highest rate of improvement in incontinence occurred in the combined  
13 intervention group, 66% compared to 11% in the control group (prevalence difference  
14 55%, 95% CI 43%-67%), yielding a number-needed-to-treat of 2. Thirty percent of  
15 the combined group reported significant improvement compared to 6% of controls  
16 (prevalence difference 23%, 95% CI 10%-36%, number-needed-to-treat of 5). In  
17 adjusted analyses, the likelihood of achieving a significant improvement in urinary  
18 symptoms from exposure to the combined intervention was five times greater than  
19 exposure to the control intervention (OR 4.94, 95% CI 1.45-16.86). Compared to  
20 controls, the participants in the combined intervention reported an adjusted mean 2.05  
21 point (95% CI 0.87-3.24) greater improvement on the ICIQ from baseline to 3-month  
22 follow up. The adjusted mean difference in ICIQ scores was also significantly higher  
23 for the continence education group compared to the control group (1.33 point greater  
24 improvement (95% CI 0.33-2.32)), but not for the self-management group. The per  
25 protocol analysis for the primary outcome and the intra-cluster correlation coefficients  
26 for each analysis are shown in Table 2.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 **Key secondary outcomes**

42 Table 3 shows the changes in incontinence-related knowledge attributable to receipt  
43 of each intervention. Participants exposed to the combined intervention showed the  
44 greatest acquisition in knowledge, exhibiting significant within-group improvement  
45 on 6 out of 8 questionnaire items. Participants learned that incontinence is not an  
46 inevitable or irreversible part of aging, that losing weight, changing the type of fluid  
47 intake and performing pelvic floor muscle exercises can reduce urinary symptoms,  
48 and that wearing undergarment protection is not always the best way to manage  
49 incontinence.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The proportion of participants with modifiable risk factors for incontinence in each  
4 group at baseline is shown in Table 1. The adoption of various risk-modifying  
5 behaviours among participants occurred to a different degree as a result of exposure to  
6 all three experimental but not the control intervention (Figure 2). At three-month  
7 follow-up, the proportion of women reporting uptake of pelvic floor muscle exercises  
8 and weight loss was significantly higher in the continence education group (46% and  
9 20% respectively), the self-management group (34% and 20%) and the combined  
10 intervention group (53% and 18%) compared to controls (8% and 3%). Many women  
11 additionally reduced their coffee intake and total fluid intake. The proportion of  
12 women who made an appointment to consult a health professional for urine leakage  
13 was 19% in the continence promotion group, 7% in the self-management group, 16%  
14 in the combined intervention group and 4% in the control group.  
15  
16  
17  
18  
19  
20  
21  
22  
23

## 24 **DISCUSSION**

25  
26  
27  
28 In this cluster-randomised trial testing the effectiveness of 3 different continence  
29 promotion interventions, we found that health education combined with the delivery  
30 of an evidence-based self-management tool via community organisations to untreated  
31 older women yielded the highest rate of urinary symptom improvement in 66% of  
32 recipients, half of whom reported significant improvements in incontinence. These  
33 outcomes translate into a number-needed-to-treat of 2 and 5 respectively, a magnitude  
34 of effect rarely achieved during public health interventions. Both new knowledge  
35 acquisition and the adoption of risk-modifying behaviours such as exercise and  
36 weight loss occurred as a result of community organisations' involvement in reaching  
37 untreated incontinent women outside the health care system.  
38  
39  
40  
41  
42  
43  
44  
45

### 46 **Strengths and weaknesses of the study**

47  
48  
49 This is the first randomised trial to test the effectiveness of continence promotion  
50 strategies through community outreach. Both explanatory mechanisms and final  
51 health outcomes were assessed, and the use of a cluster randomised design was  
52 chosen to avoid contamination of the control group.[26,27] Our choice of comparator  
53 controlled for the placebo effect of participating in a group intervention. Breaches in  
54 the fidelity and quality of implementation of the intervention were minimized by  
55  
56  
57  
58  
59  
60



1  
2  
3 having the same facilitator deliver each intervention. Improvements in urinary  
4 symptoms were shown with two validated measures, the PGI-I and the ICIQ. We  
5 believe the results have wide external validity as the community groups included  
6 women with varied educational levels and wide socioeconomic status.  
7  
8

9  
10  
11 The results of this study confirm findings from previous randomised trials suggesting  
12 a positive effect of continence education and self-monitoring strategies on urinary  
13 symptom improvement in untreated incontinent individuals.[28-33] However all  
14 previous trials invited participants for clinical assessments prior to the delivery of the  
15 intervention, or involved individualized education sessions. The current trial delivered  
16 group continence interventions without medical or nursing evaluations, in a true  
17 public health approach, to both continent and incontinent women as part of the regular  
18 activities offered by each community organisation. Rates of improvement reported in  
19 this trial on the PGI-I were similar to or exceeded those reported in other studies using  
20 self-help booklets, in the range of 50%. Because of the nature of recruitment and  
21 delivery of the intervention via community organisations, bladder diaries and pad tests  
22 could not be collected at baseline. The results of our trial can therefore not be directly  
23 compared to other trials that used more objective measures of symptom improvement.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

34  
35 Other limitations apply. Due to the nature of recruiting potential participants,  
36 individuals could not be screened and enrolled in the trial prior to randomisation of  
37 the clusters.[27] The result was an imbalance between groups, accounted for by  
38 analyses that took into account group differences in age, health status and baseline  
39 incontinence severity. The trial was not designed to measure the dose-response of  
40 knowledge acquisition and behaviour change on urinary symptom improvement. Thus  
41 only crude, dichotomous self-reported measures of behaviour change were collected  
42 and should be interpreted with caution.  
43  
44  
45  
46  
47  
48

### 49 **Relevance to the discipline**

50 The value of continence promotion interventions likely reflects the delivery method as  
51 well as the quality of the content. Group interventions that deliver continence  
52 education, self-management information, or a combination of the two will improve  
53 incontinence symptoms in 59%, 41% and 66% of recipients, respectively. It is  
54 surprising that the self-management intervention alone was not associated with  
55  
56  
57  
58  
59  
60

1  
2  
3 significant improvement compared to sham control in this trial. This can potentially  
4 be explained by the fact that continence education was completely omitted from the  
5 self-management workshop, whereas some information on bladder functioning was  
6 provided to participants during the initial work that tested the self-management tool.<sup>19</sup>  
7  
8  
9

### 10 11 **Implications for practice**

12 Implementation of community-based programs that promote behavioural techniques  
13 as first-line management for incontinence support evidence for the superior efficacy  
14 and tolerability of conservative management approaches over pharmacological  
15 treatment for incontinence.[34] As “silent sufferers” become better informed that  
16 effective strategies exist for improving urinary symptoms, patient demand for care  
17 will likely increase. Almost 20% of women made an appointment to discuss urine  
18 leakage with a health professional in the three months following receipt of the  
19 continence education intervention. Evidence-based guidelines exist for physicians to  
20 evaluate and manage urinary incontinence when first-line behavioural strategies fail,  
21 and will need to be more frequently applied.[5,11]  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 In conclusion, continence education combined with self-management delivered via  
32 community organisations to untreated older women with incontinence leads to  
33 symptom improvement in 1 out of every 2 recipients. At the current time, the majority  
34 of older women with incontinence do not seek care, and either self-manage their  
35 symptoms inappropriately or use protection to palliate urine leakage.[1-4] As  
36 incontinence is associated with multimorbidity and other deleterious health effects,  
37 results from this trial provide strong justification for public health outreach via  
38 community organisations to reduce urine leakage among untreated individuals.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Acknowledgments

We wish to acknowledge the assistance of Mira Jabbour and Francine Giroux for their expert help with database management and the data analyses. Nikki Cotterill, Adele Long aided with recruitment in the Bristol area. The above-mentioned individuals received financial compensation for their contribution to this work. We express gratitude to all the participants who took part in this trial. Although not exhaustive, particular thanks are offered to the following organisations and groups for participating in the trial: the Women's Institute, AGE UK, the University of the Third Age, Queens Nursing Institute (Scotland), Kinship Carers, the Women's Guild, Hanover Housing Association, Good Neighbours, Asian Carers Groups, Older Peoples Forum throughout the UK.

## Author Contribution Statement

Cara Tannenbaum designed the study and participated in the data analysis and interpretation. She wrote the first draft of the manuscript. Rona Agnew was responsible for data collection, participated in the data analysis and interpretation and critically reviewed the manuscript. Andrea Benedetti was responsible for the data analysis and interpretation and critically reviewed the manuscript. Doneal Thomas conducted the analyses and reviewed the manuscript. Eleanor van den Heuvel helped design the study, participated in the study implementation, helped interpret the findings and critically reviewed the manuscript.

## Data Access and Sharing Statement

Cara Tannenbaum, Doneal Thomas and Andrea Benedetti had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Patient level data and the full dataset is available upon request from the authors. Consent for data sharing was not obtained but the presented data are anonymised and the risk of identification is low.

## Competing interests

1  
2  
3 Cara Tannenbaum declares having been an advisory board member or received  
4 speaker honoraria from Pfizer, Watson, Astellas, Allergen and Ferring  
5 pharmaceuticals in the past 3 years, but not in relation to this work. All other authors  
6 declare: no support from any organisation for the submitted work; no financial  
7 relationships with any organisations that might have an interest in the submitted work  
8 in the previous three years, and no other relationships or activities that could appear to  
9 have influenced the submitted work.  
10  
11  
12  
13

### 14 15 16 **Funding and Sponsor's Role** 17

18  
19 The trial was funded by a joint collaboration between the Canadian Institutes of  
20 Health Research and the Economic and Social Research Council (UK). The authors  
21 retained full independence from the study sponsors in the design and conduct of the  
22 study; collection, management, analysis, and interpretation of the data; preparation,  
23 review, and approval of the manuscript; and decision to submit the manuscript for  
24 publication.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Sexton CC, Coyne KS, Thompson C, Bavendam T, Chen CI, Markland A. Prevalence and effect on health-related quality of life of overactive bladder in older Americans: Results from the Epidemiology of Lower Urinary Tract Symptoms Study. *J Am Geriatr Soc* 2011;**59**:1465–1470.
2. Tannenbaum C, Corcos J, Assalian P. The relationship between sexual activity and urinary incontinence in older women. *J Am Geriatr Soc* 2006;**54**:1220-4.
3. O'Donnell M, Lose G, Sykes D, Voss S, Hunskaar S. Help-seeking behaviour and associated factors among women with urinary incontinence in France, Germany, Spain and the United Kingdom. *Eur Urol* 2005;**47**:385-92
4. Herschorn S, Gajewski J, Schulz J, Corcos J. A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey. *BJU Int* 2008;**101**:52-8.
5. Bland DR et al. The effects of implementation of the Agency for Health Care Policy and Research urinary incontinence guidelines in primary care. *J Am Geriatr Soc* 2003;**51**:979–984.
6. Subak LL, Wagner TH. Talking about incontinence: the first step toward prevention and treatment. *JAMA* 2010;**303**:2184-2185.
7. Tannenbaum C, Gray M, Hoffstetter S, Cardozo L. Comorbidities associated with bladder dysfunction. *Int J Clin Pract* 2013;**67**:105-13.
8. Farage MA, Miller KW, Berardesca E, Maibach HI. Psychosocial and societal burden of incontinence in the aged population. *Arch Gynecol Obstet* 2008;**277**:285-290.
9. Holroyd-Leduc JM, Mehta KM, Covinsky KE. Urinary incontinence and its association with death, nursing home admission, and functional decline. *J Am Geriatr Soc* 2004;**52**:712-8.
10. Chiarelli PE, Mackenzie LA, Osmotherly PG. Urinary incontinence is associated with an increase in falls: a systematic review. *Aust J Physiother* 2009;**55**:89-95.
11. Holroyd-Leduc JM, Tannenbaum C, Thorpe KE, Straus SE. What type of urinary incontinence does this woman have? *JAMA* 2008;**299**:1446-56.
12. Goode PS, Burgio KL, Richter HE, Markland AD. Incontinence in older women. *JAMA* 2010;**303**:2172-81.

13. Tannenbaum C, Bachand, G, DuBeau CE, Kuchel GA. Experience of an incontinence clinic for older women : no apparent age limit for potential physical and psychological benefits. *J Women Health Gend Based Med* 2001;**10**:751-56.
14. Tannenbaum C, Brouillette J, Corcos J. Rating improvements in urinary incontinence: do patients and physicians agree? *Age Ageing* 2008;**37**:1-5
15. Newman DK, Buckley B, Gordon D et al. Continence promotion, education and primary prevention. In Abrams P, Cardozo L, Khoury S, Wein A eds: *Incontinence*. 5<sup>th</sup> International Consultation on Incontinence, Paris, February 2012. Health Publication Ltd 2013.
16. Agnew R, van den Heuvel E, Tannenbaum C. Efficiency of using community organisations as catalysts for recruitment to continence promotion trials. *Clin Trials* 2013;**10**:151-9.
17. Tannenbaum C, Drali R, Holroyd-Leduc J Richard L. Lessons learned: Impact of a continence promotion activity for older community dwelling women. *Neurourol Urodyn* 2010;**29**:540-544.
18. Wilde MH, Bliss DZ, Booth J, Cheater F, Tannenbaum C. Self-Management of Urinary and Fecal Incontinence. *AJN* 2013 in press.
19. Holroyd-Leduc J, Strauss S, Thorpe K, Davis D, Schmaltz H, Tannenbaum C. Translation of evidence into a self-management tool for use by women with urinary incontinence. *Age Ageing* 2011;**40**:227-33.
20. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. *Am J Obstet Gynecol* 2003;**189**: 98–101.
21. Avery K, Donovan J, Peters TJ et al. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. *Neurourol Urodyn* 2004; **23**: 322–30.
22. Eldridge SM; Ashby D; Kerry S. Sample size for cluster randomised trials: effect of coefficient of variation of cluster size and analysis method. *Int J Epidemiol* 2006;**35**:1292-1300.
23. Ukoumunne OC, Forbes AB, Carlin JB, Gulliford MC. Comparison of the risk difference, risk ratio and odds ratio scales for quantifying the unadjusted intervention effect in cluster randomised trials. *Stat Med* 2008;**27**: 5143-5155.
24. Users' guide to the medical literature. Integrating research evidence with the care of the individual patient. *JAMA* 2000;**283**:2829-2836.

25. Hanley JA, Negassa A, Edwardes MD. GEE analysis of negatively correlated binary responses: a caution. *Stat Med* 2000;**19**:715–722.
26. Craig P, Dieppe P, Macintyre S, Mitchie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;**337**:979-983.
27. Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement: extension to cluster randomised trials. *BMJ* 2012;**345**:e5661.
28. Kincade JE, Dougherty MC, Carlson JR, Hunter GS, Busby-Whitehead J. Randomised clinical trial of efficacy of self-monitoring techniques to treat urinary incontinence in women. *Neurourol Urodyn* 2007;**26**:507-11.
29. Wagg AR, Barron D, Kirby M, Stott D, Corlett K. A randomised partially controlled trial to assess the impact of self-help vs. structured help from a continence nurse specialist in women with undiagnosed urinary problems in primary care. *Int J Clin Pract* 2007;**61**:1863-73.
30. Dougherty MC, Dwyer JW, Pendergast JF et al. A randomised trial of behavioral management for continence with older rural women. *Res Nurs Health* 2002;**25**:3-13.
31. McFall SL, Yerkes AM, Cowan LD. Outcomes of a small group educational intervention for urinary incontinence: episodes of incontinence and other urinary symptoms. *J Aging Health* 2000;**12**:250-67.
32. Milne J. The impact of information on health behaviors of older adults with urinary incontinence. *Clin Nurs Res* 2000;**9**:161-76.
33. Goode PS, Burgio KL, Locher JL et al. Effect of behavioral training with or without pelvic floor electrical stimulation on stress incontinence in women: a randomized controlled trial. *JAMA* 2003;**290**(3):345-52.
34. Shamliyan T, Wyman J, Kane RL. Nonsurgical treatments for urinary incontinence in adult women: diagnosis and comparative effectiveness. Comparative Effectiveness Review No. 36. (Prepared by the University of Minnesota Evidence-based Practice Center under Contract No. HHSA 290-2007-10064-I.) AHRQ Publication No. 11(12)-EHC074-EF. Rockville, MD. Agency for Healthcare Research and Quality. April 2012. Available at: [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm).

Table 1: Baseline characteristics and distribution of modifiable risk factors of participants

	Continence education (n=64)	Self-management (n=70)	Combined intervention (n=61)	Control intervention (n=64)
	<b>Mean ± SD</b>			
Age	70.8 ± 7.9	71.0 ± 6.8	70.4 ± 6.7	74.1 ± 8.1
Mean ICIQ score*	8.5 ± 4.4	6.8 ± 3	7.3 ± 5.6	6.7 ± 3.4
	<b>(% yes)</b>			
Lives alone	48.4	40.0	37.7	59.4
Education				
University degree or equivalent	31.2	45.7	37.7	19.0
General health perception				
Good, very good, excellent	53.1	85.7	80.3	75.0
Fair/poor	45.3	14.3	16.4	25.0
Depression	48.4	35.7	32.8	20.3
Heart disease	35.9	25.7	16.4	21.0
Falls	45.3	31.4	18.0	18.8
Arthritis	78.1	52.9	44.3	57.8
Diabetes	39.1	24.3	18.0	20.3
High blood pressure	59.0	40.0	45.9	55.6
<b>Type of incontinence</b>				
Stress only	15.6	12.9	14.8	33.3
Urgency only	32.8	35.7	29.5	20.6
Mixed	45.3	42.9	55.7	39.7
<b>Modifiable risk factors</b>				
Performs pelvic floor muscle exercises 3 times per week	18.8	15.7	11.9	15.6
Self-reported body mass index $\geq 27$ kg/m <sup>2</sup> **	53.2	53.0	42.4	49.2
Drinks more than 1.5 litres of fluid/day	43.8	44.3	54.1	37.5
Drinks one cup of tea or more/day	85.9	84.3	73.8	84.4
Drinks one cup of coffee or more/day	46.9	62.9	65.6	64.1
Smokes	6.3	4.3	4.9	6.2

\*ICIQ = International Consultation on Incontinence Questionnaire, used to measure the severity and bother from urinary incontinence. Scores range from 0 to 21, with higher scores representing worse incontinence.

1  
2  
3  
4 \*\*Self-reported body mass index: calculated as weight (kg)/height<sup>2</sup> (m) based on  
5 participant's self-reported height and weight at baseline  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 2: Prevalence, risk difference and odds ratios for self-reported improvements in incontinence at 3-months

	Prevalence at 3-month follow-up				Prevalence difference (95% CI)*			Odds ratio (95% CI)					
	Conti-nence	SM	Combined	Control	Conti-nence vs control	SM vs control	Combined vs control	Crude			Adjusted**		
								Conti-nence vs control	SM vs control	Combined vs control	Conti-nence vs control	SM vs control	Combined vs control
<b>Any improvement</b>													
Intention-to-treat	0.59	0.41	0.66	0.11	0.48 (0.33-0.64)	0.28 (0.08-0.48)	.55 (0.43-0.67)	11.72 (4.54-30.21)	5.16 (1.73-15.37)	15.51 (6.50-37.01)	9.14 (3.05-27.37)	2.71 (0.87-8.41)	17.63 (5.09-61.13)
Per protocol	0.64	0.47	0.73	0.13	0.51 (0.34-0.67)	0.29 (0.07-0.51)	0.59 (0.45-0.74)	11.45 (4.27-30.67)	4.64 (1.48-14.56)	17.14 (6.51-45.11)	10.40 (3.05-35.48)	3.46 (1.08-11.03)	23.27 (5.91-91.59)
ICC Intention-to-treat	-	-	-	-	0.02	0.18	0	0.24	0.18	0	0	0.06	0
ICC per protocol	-	-	-	-	0.03	0.25	0	0.03	0.25	0	0	0.14	0
<b>Very much better or much better</b>													
Intention-to-treat	0.22	0.21	0.30	0.06	0.16 (0.03-0.29)	0.14 (0.01-0.27)	0.23 (0.10-0.36)	4.2 (1.4-13.0)	3.8 (1.2-12.2)	6.3 (2.2-17.7)	2.83 (0.59-13.66)	1.81 (0.50-6.60)	4.94 (1.45-16.86)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Per protocol	0.24	0.24	0.33	0.08	0.16 (0.02-0.30)	0.15 (0.00-0.29)	0.26 (0.10-0.42)	3.7 (1.2-11.3)	3.5 (1.06-11.31)	5.8 (2.0-17.4)	2.51 (0.48-13.18)	2.28 (0.63-8.24)	5.32 (1.39-20.34)
ICC Intention-to-treat	-	-	-	-	0.02	0.06	0	0.02	0.06	0	0	0	0
ICC per protocol	-	-	-	-	0.01	0.08	0.02	0.01	0.08	0	0	0.02	0

SM = Self-management; ICC = intra-cluster correlation correlation

\*95% CI's were calculated using robust standard errors

\*\*Adjusted for age, living alone, depression, heart disease, falls, arthritis, diabetes, high blood pressure, educational status, general health perception, and baseline incontinence severity score

Table 3: Change in incontinence-related knowledge

		Continence education n=64	Self-management n=70	Combined intervention n=61	Control n=64
1. Urinary incontinence is a normal part of ageing	Baseline % agreement	73.0	79.7	77.0	79.7
	3 month follow up % agreement	36.2	63.9	38.2	82.7
	p value for change*	<b>&lt;0.001</b>	<b>0.02</b>	<b>&lt;0.001</b>	0.73
2. Once people start to leak urine, they are never able to control their urine again	Baseline % agreement	41.9	32.9	36.1	50.8
	3 month follow up % agreement	29.3	17.7	7.3	51.9
	p value for change	0.12	0.06	<b>&lt;0.001</b>	1
3. Urine leakage can be caused by many different things	Baseline % agreement	88.9	92.8	88.3	86.9
	3 month follow up % agreement	93.1	88.7	92.7	90.4
	p value for change	1	0.77	0.73	0.63
4. Wearing pads or diapers is the best way to manage urinary incontinence	Baseline % agreement	57.1	40.6	52.5	67.2
	3 month follow up % agreement	36.8	33.9	27.3	69.2
	p value for change	<b>0.03</b>	0.11	<b>0.001</b>	1
5. What you drink can contribute to urine leakage	Baseline % agreement	64.5	66.7	68.3	66.1
	3 month follow up % agreement	77.6	75.8	89.1	68.6

		Continen- ce education n=64	Self- man- agement n=70	Combined inter- vention n=61	Control n=64
	p value for change	0.26	0.36	<b>0.01</b>	0.77
6. How much you drink can contribute to urine leakage	Baseline % agreement	72.6	65.2	67.2	71.4
	3 month follow up % agreement	77.6	71	76.4	65.4
	p value for change	0.63	0.65	0.36	0.79
7. Losing weight can lead to improvement in incontinence	Baseline % agreement	61.3	74.3	66.1	75
	3 month follow up % agreement	77.6	77.4	90.9	80.8
	p value for change	0.08	0.69	<b>&lt;0.001</b>	0.48
8. Exercising pelvic floor muscles can help control urine leakage	Baseline % agreement	85.5	88.6	85.2	96.9
	3 month follow up % agreement	96.5	96.7	98.2	98.1
	p value for change	<b>0.04</b>	0.13	<b>0.02</b>	1.0

\* McNemar's test for matched-pairs data

Figure 1: Flow of participants through the trial





Figure 2: Change in risk-modifying behaviours at 3-month follow-up



\*Significantly different from the control group ( $p < 0.05$ ) using Fisher's Exact test in per protocol analysis  
 Error bars represent 95% confidence intervals

**Table 1: CONSORT 2010 checklist of information to include when reporting a cluster randomised trial**

Section/Topic	Item No	Standard Checklist item	Extension for cluster designs	Page No *
<b>Title and abstract</b>				
	1a	Identification as a randomised trial in the title	Identification as a cluster randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) <sup>1,2</sup>	See table 2	3-4
<b>Introduction</b>				
<b>Background and objectives</b>	2a	Scientific background and explanation of rationale	Rationale for using a cluster design	6
	2b	Specific objectives or hypotheses	Whether objectives pertain to the cluster level, the individual participant level or both	5
<b>Methods</b>				
<b>Trial design</b>	3a	Description of trial design (such as parallel, factorial) including allocation ratio	Definition of cluster and description of how the design features apply to the clusters	6
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons		-
<b>Participants</b>	4a	Eligibility criteria for participants	Eligibility criteria for clusters	6-7
	4b	Settings and locations where the data were collected		6
<b>Interventions</b>	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	Whether interventions pertain to the cluster level, the individual participant level or both	7
<b>Outcomes</b>	6a	Completely defined pre-specified primary and secondary outcome measures, including how and	Whether outcome measures pertain to the cluster level, the individual participant level or both	8

		when they were assessed		
	6b	Any changes to trial outcomes after the trial commenced, with reasons		-
<b>Sample size</b>	7a	How sample size was determined	Method of calculation, number of clusters(s) (and whether equal or unequal cluster sizes are assumed), cluster size, a coefficient of intracluster correlation (ICC or <i>k</i> ), and an indication of its uncertainty	9,26
	7b	When applicable, explanation of any interim analyses and stopping guidelines		-
<b>Randomisation:</b>				
<b>Sequence generation</b>	8a	Method used to generate the random allocation sequence		8
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	Details of stratification or matching if used	8
<b>Allocation concealment mechanism</b>	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	Specification that allocation was based on clusters rather than individuals and whether allocation concealment (if any) was at the cluster level, the individual participant level or both	8
<b>Implementation</b>	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	Replace by 10a, 10b and 10c	-
	10a		Who generated the random allocation sequence, who enrolled clusters, and who assigned clusters to interventions	8
	10b		Mechanism by which individual participants were included in clusters for the purposes of the trial (such as complete	6

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

			enumeration, random sampling)	
	10c		From whom consent was sought (representatives of the cluster, or individual cluster members, or both), and whether consent was sought before or after randomisation	6
<b>Blinding</b>	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how		8
	11b	If relevant, description of the similarity of interventions		8
<b>Statistical methods</b>	12a	Statistical methods used to compare groups for primary and secondary outcomes	How clustering was taken into account	9-10
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses		9-10
<b>Results</b>				
<b>Participant flow (a diagram is strongly recommended)</b>	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	For each group, the numbers of clusters that were randomly assigned, received intended treatment, and were analysed for the primary outcome	26
	13b	For each group, losses and exclusions after randomisation, together with reasons	For each group, losses and exclusions for both clusters and individual cluster members	26
<b>Recruitment</b>	14a	Dates defining the periods of recruitment and follow-up		6
	14b	Why the trial ended or was stopped		-
<b>Baseline data</b>	15	A table showing baseline demographic and clinical	Baseline characteristics for the individual and cluster levels as	20



		characteristics for each group	applicable for each group	
<b>Numbers analysed</b>	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	For each group, number of clusters included in each analysis	26
<b>Outcomes and estimation</b>	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	Results at the individual or cluster level as applicable and a coefficient of intracluster correlation (ICC or $k$ ) for each primary outcome	11,22-25
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended		11,22-25
<b>Ancillary analyses</b>	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory		11,22-25
<b>Harms</b>	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms <sup>3</sup> )		-
<b>Discussion</b>				
<b>Limitations</b>	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses		12
<b>Generalisability</b>	21	Generalisability (external validity, applicability) of the trial findings	Generalisability to clusters and/or individual participants (as relevant)	13-14
<b>Interpretation</b>	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence		13-14
<b>Other information</b>				
<b>Registration</b>	23	Registration number and		4

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

		name of trial registry	
<b>Protocol</b>	24	Where the full trial protocol can be accessed, if available	-
<b>Funding</b>	25	Sources of funding and other support (such as supply of drugs), role of funders	4,16

\* Note: page numbers optional depending on journal requirements

For peer review only

**Table 2: Extension of CONSORT for abstracts<sup>1,2</sup> to reports of cluster randomised trials**

Item	Standard Checklist item	Extension for cluster trials
<b>Title</b>	Identification of study as randomised	<b>Identification of study as cluster randomised</b>
<b>Trial design</b>	Description of the trial design (e.g. parallel, cluster, non-inferiority)	
<b>Methods</b>		
<b>Participants</b>	Eligibility criteria for participants and the settings where the data were collected	<b>Eligibility criteria for clusters</b>
<b>Interventions</b>	Interventions intended for each group	
<b>Objective</b>	Specific objective or hypothesis	<b>Whether objective or hypothesis pertains to the cluster level, the individual participant level or both</b>
<b>Outcome</b>	Clearly defined primary outcome for this report	<b>Whether the primary outcome pertains to the cluster level, the individual participant level or both</b>
<b>Randomization</b>	How participants were allocated to interventions	<b>How clusters were allocated to interventions</b>
<b>Blinding (masking)</b>	Whether or not participants, care givers, and those assessing the outcomes were blinded to group assignment	
<b>Results</b>		
<b>Numbers randomized</b>	Number of participants randomized to each group	<b>Number of clusters randomized to each group</b>
Recruitment	Trial status <sup>1</sup>	
<b>Numbers analysed</b>	Number of participants analysed in each group	<b>Number of clusters analysed in each group</b>
<b>Outcome</b>	For the primary outcome, a result for each group and the estimated effect size and its precision	<b>Results at the cluster or individual participant level as applicable for each primary outcome</b>
<b>Harms</b>	Important adverse events or side effects	
<b>Conclusions</b>	General interpretation of the results	
<b>Trial registration</b>	Registration number and name of trial register	
<b>Funding</b>	Source of funding	

<sup>1</sup> Relevant to Conference Abstracts

## REFERENCES

- 1 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomised trials in journal and conference abstracts. *Lancet* 2008, 371:281-283
- 2 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG at al (2008) CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. *PLoS Med* 5(1): e20
- 3 Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D. Better reporting of harms in randomized trials: an extension of the CONSORT statement. *Ann Intern Med* 2004; 141(10):781-788.



**Effectiveness of continence promotion for older women via community organisations: a cluster randomised trial**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004135.R1
Article Type:	Research
Date Submitted by the Author:	05-Nov-2013
Complete List of Authors:	Tannenbaum, Cara; Université de Montréal, Faculty of Medicine Agnew, Rona; Glasgow Caledonian University, Benedetti, Andrea; McGill University, Departments of Medicine and of Epidemiology, Biostatistics & Occupational Health Thomas, Doneal; McGill University, Departments of Medicine and of Epidemiology, Biostatistics & Occupational Health van den Heuvel, Eleanor; Brunel University,
<b>Primary Subject Heading</b>:	Urology
Secondary Subject Heading:	Geriatric medicine
Keywords:	Urinary incontinences < UROLOGY, PUBLIC HEALTH, GERIATRIC MEDICINE

SCHOLARONE™  
Manuscripts

Effectiveness of continence promotion for older women via community organisations:  
a cluster randomised trial

Cara Tannenbaum, MD, MSc<sup>1</sup> Rona Agnew, PhD<sup>2</sup> Andrea Benedetti, PhD<sup>3</sup> Doneal  
Thomas, MSc<sup>4</sup> Eleanor van den Heuvel, PhD<sup>5</sup>

<sup>1</sup>Associate Professor, Faculty of Medicine, Université de Montréal, Quebec, Canada

<sup>2</sup>Clinical Research Fellow, Glasgow Caledonian University, Glasgow, UK

<sup>3</sup>Associate Professor, Departments of Medicine and of Epidemiology, Biostatistics &  
Occupational Health, McGill University, Quebec, Canada

<sup>4</sup>PhD candidate, Department of Epidemiology, Biostatistics & Occupational Health,  
McGill University, Quebec, Canada

<sup>5</sup>Director of Assistive Technology Programme, Brunel Institute for Ageing Studies,  
Brunel University, Uxbridge, UK

Word count : 3182

Key words: Continence promotion, cluster trial, community organisations, older  
women, urinary incontinence

Corresponding Author: Dr. Cara Tannenbaum, Centre de Recherche de l'Institut  
universitaire de gériatrie de Montréal, 4545 Queen Mary Road, Montreal, Quebec,  
Canada H3W 1W5. Tel (514) 340-2800. Fax : (514) 340-3530.

Email: [cara.tannenbaum@umontreal.ca](mailto:cara.tannenbaum@umontreal.ca)

The Corresponding Author has the right to grant on behalf of all authors and does  
grant on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ  
Publishing Group Ltd to permit this article (if accepted) to be published in BMJ Open  
editions and any other BMJ PGL products and sublicences such use and exploit all  
subsidiary rights, as set out in the licence.

1  
2  
3 All authors have completed the Unified Competing Interest form at  
4 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding  
5 author) and declare: no support from any organisation for the submitted work; no  
6 financial relationships with any organisations that might have an interest in the  
7 submitted work in the previous three years, and no other relationships or activities that  
8 could appear to have influenced the submitted work.  
9  
10  
11  
12

13  
14 The authors retained full independence from the study sponsors in the design,  
15 implementation, analysis, interpretation and reporting of the findings.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objectives:** The primary objective of this cluster randomised controlled trial was to compare the effectiveness of the three experimental continence promotion interventions against a control intervention on urinary symptom improvement in older women with untreated incontinence recruited from community organisations. A second objective was to determine whether changes in incontinence-related knowledge and new uptake of risk-modifying behaviours explain these improvements.

**Setting:** 71 community organisations across the United Kingdom

**Participants:** 259 women aged 60 years and older with untreated incontinence entered the trial; 88% completed the 3-month follow-up.

**Interventions:** The three active interventions consisted of a single 60-minute group workshop on 1) continence education (20 clusters, 64 women); 2) evidence-based self-management (17 clusters, 70 women); or 3) combined continence education and self-management (17 clusters, 61 women). The control intervention was a single 60-minute educational group workshop on memory loss, polypharmacy and osteoporosis (17 clusters, 64 women).

**Primary and secondary outcome measures:** The primary outcome was self-reported improvement in incontinence 3 months post-intervention at the level of the individual. The secondary outcome was change in the International Consultation on Incontinence Questionnaire (ICIQ) from baseline to 3-month follow-up. Changes in incontinence-related knowledge and behaviours were also assessed.

**Results:** The highest rate of urinary symptom improvement occurred in the combined intervention group (66% vs 11% of the control group, prevalence difference 55%, 95% CI 43%-67%, intraclass correlation 0). Thirty percent versus 6% of participants reported significant improvement respectively (prevalence difference 23%, 95% CI 10%-36%, intraclass correlation 0). The number-needed-to-treat was 2 to achieve any improvement in incontinence symptoms, and 5 to attain significant improvement. Compared to controls, participants in the combined intervention reported an adjusted



1  
2  
3 mean 2.05 point (95% CI 0.87-3.24) greater improvement on the ICIQ from baseline  
4 to 3-month follow up. Changes in knowledge and self-reported risk-reduction  
5 behaviours paralleled rates of improvement in all intervention arms.  
6  
7  
8

9  
10 **Conclusion:** Continence education combined with evidence-based self-management  
11 improves symptoms of incontinence among untreated older women. Community  
12 organisations represent an untapped vector for delivering effective continence  
13 promotion interventions.  
14  
15

16  
17  
18 **Trial registration:** ClinicalTrials.gov ID number NCT01239836  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Article Summary : Strengths and limitations of this study

- First study to provide Level 1 evidence that continence promotion is an effective strategy for improving urinary symptoms among untreated community-dwelling older women
- Participants were recruited via community organisations with representation across diverse socio-economic strata
- Rates of knowledge acquisition and behaviour change provide an explanatory mechanism for the observed improvements in incontinence in participants receiving the combined education plus self-management strategy
- Only self-reported outcomes and crude dichotomous measures of behaviour change were collected so results must be interpreted with caution

## Introduction

Urinary incontinence is more frequent than breast cancer, heart disease or diabetes among older women, but remains a stigmatized and untreated condition despite its high prevalence. [1-4] In the United States, Canada, the U.K. and other European countries, up to 40% of women aged 65 years and older experience involuntary urine leakage, but little more than 15-30% seek care.[1-4] Even fewer physicians feel competent evaluating or treating incontinence.[5-6] Urinary incontinence is associated with obesity, cardiovascular disease, diabetes, depression, social isolation, decline in function, falls, nursing home admission, and onerous out-of-pocket expenses.[6-10] In many cases incontinence can be improved, and even cured, when evidence-based diagnostic and treatment strategies are appropriately applied.[6,11-14]

It is a commonly held misconception that incontinence is a normal part of aging.[15] Not-for-profit organisations seek to raise continence awareness worldwide and promote treatment for incontinent individuals. Media campaigns, brochures and public awareness lectures attempt to de-stigmatise incontinence and increase help-seeking, but the effectiveness of these initiatives for reaching their target population remains unknown.[15] Transmission of public health education via community organisations is an unexplored strategy for improving urinary symptoms.[16] Data from randomised trials are needed to determine whether the delivery of an evidence-based continence intervention via community organisations is an effective method for treating incontinence.

The primary objective of this cluster randomised controlled trial was to compare the effectiveness of the three experimental continence promotion interventions against a control intervention on urinary symptom improvement in older women with untreated incontinence recruited from community organisations. A second objective was to determine whether changes in incontinence-related knowledge, attitudes and new uptake of risk-modifying behaviours explain improvements in incontinence. We hypothesized that continence education combined with evidence-based self-management would yield the greatest improvement in incontinence symptoms, measured at the level of the individual, 3-months post-intervention.

## METHODS

### Study design and oversight

A 4 arm, parallel-group, controlled, cluster randomised trial was conducted. The study design, recruitment methods and interventions have been reported.[16] Clustering was at the level of the community organisation, from whence participants were recruited. The choice of a cluster design served to prevent contamination between participants in the same community organisation. The trial was designed by two of the authors and was overseen by the full investigator team, which had full access to the data. The data were collected at community organisations across the United Kingdom. All participants provided written informed consent. The protocol was approved by the Brunel University Research Ethics Committee.

### Study population and recruitment

Inclusion criteria for community organisations included any organisation throughout the United Kingdom that consented to participate in the trial between November 2010 and September 2012. A community organisation was loosely defined as any not-for-profit group of individuals with a shared interest. These included interest and charity groups, seniors' housing groups, women's lobby groups and Asian caregiver associations.[16] Organisations were contacted strategically by convenience sampling, word of mouth and referral. A research coordinator approached community organisations to join the trial by telephone, email and newspaper advertising.

Inclusion criteria for participants were women aged 60 years and older who reported urinary incontinence at least once weekly on the International Consultation on Incontinence Questionnaire (ICIQ), and who were not under active treatment for incontinence. For privacy reasons, many community organisations were uncomfortable screening their members for incontinence in advance, so eligibility to participate in the trial could only be ascertained by the research coordinator on the day of delivery of the intervention.[16] Eligibility to participate in the trial was established by asking all attendees at the workshop to complete a baseline screening questionnaire upon arrival. At this time, a study information sheet and consent form were distributed to all participants. All women, regardless of eligibility or desire to enrol in

1  
2  
3 the trial, were permitted to stay for the workshop. Only those women who wished to  
4 enrol in the trial submitted the signed consent form to the workshop facilitator  
5 following delivery of the intervention, however all attendees were encouraged to  
6 submit the baseline screening questionnaire even if they were continent or did not  
7 wish to participate in the trial.  
8  
9  
10

### 11 12 13 **Interventions**

14  
15  
16 The interventions were applied at the level of each cluster. The three experimental  
17 interventions to be tested were continence education, self-management including the  
18 distribution of an evidence-based risk factor reduction tool for incontinence, and a  
19 combined intervention that included both components. The sham control intervention  
20 was a lecture on health promotion for older women that addressed topics other than  
21 incontinence. All interventions were delivered once in group format to 8-16 women  
22 by the same facilitator at a venue of the organisation's choosing, and lasted 60-90  
23 minutes. A slide presentation with a pre-established script prepared for the facilitator  
24 was delivered at each workshop.  
25  
26  
27  
28  
29  
30  
31

32  
33 The continence promotion intervention incorporated elements of constructivist  
34 learning that challenged older adults' erroneous beliefs about accepting incontinence  
35 as a normal part of aging, and aimed to change attitudes and create new knowledge  
36 about the different types, etiology, risk factors and treatment options for urine  
37 loss.[16-17] The self-management workshop reviewed self-management theory in an  
38 interactive format, and provided a customised evidence-based self-management  
39 program for risk factor modification for incontinence to each participant.[18-19] The  
40 program targeted pelvic floor muscle weakness, obesity, consumption of caffeinated  
41 beverages, smoking, vision loss and constipation, with instructions on how to keep a  
42 bladder diary to help monitor symptoms. The content of the combined intervention  
43 condensed elements from the continence promotion workshop along with self-  
44 management theory, and provided the customized self-management tool to  
45 participants. The control intervention addressed other non-bladder related aspects of  
46 older women's health such as memory problems, polypharmacy, osteoporosis,  
47 nutrition, physical fitness and vision impairment.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Study Outcomes

The primary outcome was the participant's global impression of improvement in incontinence symptoms, measured at 3 months post-intervention by telephone interview using the patient's global impression of improvement (PGI-I) questionnaire. The PGI-I is a validated, single-item global rating of change scale that asks the patient to describe how their incontinence condition is now compared to how it was prior to the intervention (very much better, much better, a little bit better, no change, a little bit worse, much worse and very much worse).[20] The primary outcome, any improvement, was defined as a rating of a little bit better, much better or very much better. A secondary outcome, significant improvement, was defined as much better or very much better. The ICIQ, which measures the frequency, severity and bother from incontinence was used at baseline to screen participants for inclusion to the trial, and was repeated at follow-up.[21] The ICIQ diagnostic item was used by participants to describe the type of incontinence at baseline. A pre- and post-8-item questionnaire on knowledge and attitudes towards incontinence was administered at baseline and at 3-month follow-up, as were risk factors and behaviors related to incontinence.[17] Risk factors and behaviors included performance of pelvic floor muscle exercises three times weekly (yes, no), daily consumption of 1 cup or more of tea or coffee (yes, no), fluid intake > 1.5 L/day (yes, no), weight and height (self-report) and smoking status (yes, no). At three month follow-up participants were asked whether they had sought treatment for urine leakage during the past 3 months. All follow-up interviews were performed by the research coordinator, who was blinded to participant identification.

The original study protocol sought to examine reductions in urinary frequency as measured on a bladder diary and reductions in the cost of pad use as primary and secondary outcomes respectively. However as soon as recruitment for the trial commenced it became apparent that distribution of bladder diaries and objective measurement of pad use pre-intervention would not be possible. This occurred as a result of privacy concerns expressed by participating community organisations for revealing and sharing their members' names and contact information with the research team prior to the delivery of the workshops.[16] The PGI-I was therefore used as the revised primary measure of effectiveness from the onset of the trial. Data on self-efficacy for managing incontinence was also collected, but is not reported in

1  
2  
3 this paper due to problems with comprehension of the visual analogue response scale  
4 during the 3-month telephone follow-up that occurred non-differentially among  
5 participants in all arms of the study.  
6  
7  
8

### 9 10 **Randomisation and allocation concealment**

11 Group allocation occurred by non-stratified randomisation in blocked groups of 4 of  
12 consenting organisations that agreed to host a workshop. An independent statistician  
13 at a distant study site was responsible for randomisation using computer-generated  
14 random digits. Community organisations were informed that one of four workshops  
15 would be delivered on health topics of interest to older women, but not which one. In  
16 this way, group allocation was concealed from both the clusters and the individual  
17 participants, who were invited by the host organisation to attend a “Women’s Health  
18 Workshop”. The research coordinator remained unaware of group allocation at the  
19 time each community organisation was recruited to the trial because she was only  
20 informed which workshop to prepare for each organisation several days before each  
21 workshop. The trial is considered open-label because both the research facilitator who  
22 delivered the intervention and the participants who received it were aware of which  
23 intervention was being delivered.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

### 34 **Sample Size**

35 The trial was designed to detect a minimal 35% difference in the number of  
36 participants reporting any improvement (very much better, much better, a little bit  
37 better on the PGI-I) between the experimental and control conditions, assuming a rate  
38 of improvement in the control condition as high as 20%, with 80% power and alpha  
39 0.05 two-sided (n=34). Using an inflation factor of 1.65 to account for an anticipated  
40 maximum intracluster correlation (ICC) of 0.05 and unequal cluster size yielded a  
41 recruitment target of 56 participants per group.[22]  
42  
43  
44  
45  
46  
47  
48

### 49 **Statistical Methods**

50 Differences in baseline characteristics between the four groups were determined. To  
51 assess the primary outcome we estimated the unadjusted risk difference (prevalence  
52 of the outcome) and 95% confidence intervals (CI) via generalized estimating  
53 equations (GEEs) for participants who reported any improvement on the PGI-I. We  
54 repeated the same analysis for those who reported significant improvement. GEEs  
55  
56  
57  
58  
59  
60



1  
2  
3 with an identity link and an exchangeable correlation structure were used to account  
4 for possible correlation between women in the same organisation.[23] To adjust for  
5 the imbalance in potential confounders in the groups at baseline, additional analyses  
6 were conducted using multivariable logistic regression estimated via GEE with an  
7 exchangeable correlation structure. Potential confounders included age and baseline  
8 incontinence severity (ICIQ score) as continuous predictors, and living alone,  
9 depression, heart disease, falls, arthritis, diabetes, high blood pressure, educational  
10 status and general health perception as dichotomous predictors. Both intent-to-treat  
11 (ITT) and per protocol (PP) analyses were performed. For the ITT analysis,  
12 participants with missing data were assumed to have no change in incontinence status  
13 at three-month follow-up. The number needed to treat was calculated as the inverse of  
14 the difference in absolute event rates between the experimental and control  
15 groups.[24] We report intra-cluster (intra-community organisation) correlation  
16 coefficients (ICC) from the marginal model using GEE with assumed exchangeable  
17 correlation structure and robust standard errors.[25] In cases where an  $ICC < 0$  was  
18 detected, we assumed a correlation structure of independence, but still used the  
19 robust variance estimator. The robust variance estimator is robust to misspecification  
20 of the correlation structure, so standard errors, confidence intervals and p values are  
21 still correct. To estimate adjusted mean group differences in ICIQ scores from  
22 baseline to 3-month follow up, we used GEE with a Gaussian regression model for  
23 continuous outcomes and followed the same procedure outlined above.

24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40 Improvements in incontinence-related knowledge by intervention type for proportions  
41 of individuals responding correctly to each knowledge questionnaire item at baseline  
42 compared to 3-month follow-up were estimated using McNemar's test for matched  
43 pair analysis. Rates of improvement in self-reported risk modifying behaviours for  
44 incontinence were calculated, along with 95% confidence intervals. Differences in  
45 improvement rates between the intervention and the control group were compared  
46 using Fisher's Exact test using a per protocol analysis. A difference in response for  
47 each health behavior item that indicated adoption of a new risk modifying behaviour  
48 was defined as a positive change at 3-month follow-up compared to baseline.

49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
60 Reduced coffee and tea intake refer to individuals who reduced their consumption to a  
single cup per day or less. Weight loss was determined by a positive response to the  
question, "Has your weight changed (yes, no) and if so, how much do you now



weigh?" and evidence of self-reported current weight lower than self-reported weight at baseline. All statistical analyses were run using RStudio 0.97.310.0, an integrated development environment for R.

## RESULTS

### Study participants and follow-up

Four-hundred-and-twenty different community organisations were approached over an 18-month period to participate in the trial. Of these, 17% consented and succeeded in hosting an intervention, yielding 71 clusters that were randomised. Approximately one quarter of the groups contacted refused; 2% expressed interest but were unable to organise a workshop; and a little over half failed to give any response although most of them had been followed up and had received extra information on the project.<sup>16</sup> Figure 1 depicts the study flow of the clusters and participants through the trial. Seven-hundred-and-sixty three women attended the workshops, of whom 322 (42%) were known to be eligible for the trial. The mean number of participants recruited from each cluster for the continence promotion group was  $3 \pm 2$ , whereas it was  $4 \pm 2$  for the other 3 groups. Eighty-percent (259/322) of known eligible attendees to the workshops consented to take part in the trial. Two-hundred-and-twenty-eight of these (88%) were available for 3-month follow-up. Table 1 compares the baseline characteristics of participants in each trial arm.

### Primary and secondary outcomes

The highest rate of improvement in incontinence occurred in the combined intervention group, 66% compared to 11% in the control group (prevalence difference 55%, 95% CI 43%-67%), yielding a number-needed-to-treat of 2. Thirty percent of the combined group reported significant improvement compared to 6% of controls (prevalence difference 23%, 95% CI 10%-36%, number-needed-to-treat of 5). In adjusted analyses, the likelihood of achieving a significant improvement in urinary symptoms from exposure to the combined intervention was five times greater than exposure to the control intervention (OR 4.94, 95% CI 1.45-16.86). Compared to controls, the participants in the combined intervention reported an adjusted mean 2.05 point (95% CI 0.87-3.24) greater improvement on the ICIQ from baseline to 3-month follow up. The adjusted mean difference in ICIQ scores was also significantly higher

1  
2  
3 for the continence education group compared to the control group (1.33 point greater  
4 improvement (95% CI 0.33-2.32)), but not for the self-management group. The per  
5 protocol analysis for the primary outcome and the intra-cluster correlation coefficients  
6 for each analysis are shown in Table 2.  
7  
8  
9

### 10 11 **Other outcomes**

12 Table 3 shows the changes in incontinence-related knowledge attributable to receipt  
13 of each intervention. Participants exposed to the combined intervention showed the  
14 greatest acquisition in knowledge, exhibiting significant within-group improvement  
15 on 6 out of 8 questionnaire items. Participants learned that incontinence is not an  
16 inevitable or irreversible part of aging, that losing weight, changing the type of fluid  
17 intake and performing pelvic floor muscle exercises can reduce urinary symptoms,  
18 and that wearing undergarment protection is not always the best way to manage  
19 incontinence.  
20  
21  
22  
23  
24  
25  
26  
27

28 The proportion of participants with modifiable risk factors for incontinence in each  
29 group at baseline is shown in Table 1. The adoption of various risk-modifying  
30 behaviours among participants occurred to a different degree as a result of exposure to  
31 all three experimental but not the control intervention (Figure 2). At three-month  
32 follow-up, the proportion of women reporting uptake of pelvic floor muscle exercises  
33 and weight loss was significantly higher in the continence education group (46% and  
34 20% respectively), the self-management group (34% and 20%) and the combined  
35 intervention group (53% and 18%) compared to controls (8% and 3%). Many women  
36 additionally reduced their coffee intake and total fluid intake. The proportion of  
37 women who made an appointment to consult a health professional for urine leakage  
38 was 19% in the continence promotion group, 7% in the self-management group, 16%  
39 in the combined intervention group and 4% in the control group.  
40  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **DISCUSSION**

50  
51  
52 In this cluster-randomised trial testing the effectiveness of 3 different continence  
53 promotion interventions, we found that health education combined with the delivery  
54 of an evidence-based self-management tool via community organisations to untreated  
55 older women yielded the highest rate of urinary symptom improvement in 66% of  
56  
57  
58  
59  
60

1  
2  
3 recipients, half of whom reported significant improvements in incontinence. These  
4 outcomes translate into a number-needed-to-treat of 2 and 5 respectively, a magnitude  
5 of effect rarely achieved during public health interventions. Both new knowledge  
6 acquisition and the adoption of risk-modifying behaviours such as exercise and  
7 weight loss occurred as a result of community organisations' involvement in reaching  
8 untreated incontinent women outside the health care system.  
9  
10  
11  
12

### 13 **Strengths and weaknesses of the study**

14  
15  
16  
17 This is the first randomised trial to test the effectiveness of continence promotion  
18 strategies through community outreach. Both explanatory mechanisms and final  
19 health outcomes were assessed, and the use of a cluster randomised design was  
20 chosen to avoid contamination of the control group.[26,27] Our choice of comparator  
21 controlled for the placebo effect of participating in a group intervention. Breaches in  
22 the fidelity and quality of implementation of the intervention were minimized by  
23 having the same facilitator deliver each intervention. Improvements in urinary  
24 symptoms were shown with two validated measures, the PGI-I and the ICIQ. We  
25 believe the results have wide external validity as the community groups included  
26 women with varied educational levels and wide socioeconomic status.  
27  
28  
29  
30  
31  
32  
33  
34

35  
36 The results of this study confirm findings from previous randomised trials suggesting  
37 a positive effect of continence education and self-monitoring strategies on urinary  
38 symptom improvement in untreated incontinent individuals.[28-33] However all  
39 previous trials invited participants for clinical assessments prior to the delivery of the  
40 intervention, or involved individualized education sessions. The current trial delivered  
41 group continence interventions without medical or nursing evaluations, in a true  
42 public health approach, to both continent and incontinent women as part of the regular  
43 activities offered by each community organisation. Rates of improvement reported in  
44 this trial on the PGI-I were similar to or exceeded those reported in other studies using  
45 self-help booklets, in the range of 50%. Because of the nature of recruitment and  
46 delivery of the intervention via community organisations, bladder diaries and pad tests  
47 could not be collected pre-intervention. The results of our trial can therefore not be  
48 directly compared to other trials that used more objective measures of symptom  
49 improvement.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 Other limitations apply. Due to the nature of recruiting potential participants,  
6 individuals could not be screened and enrolled in the trial prior to randomisation of  
7 the clusters.[27] The result was an imbalance between groups, accounted for by  
8 analyses that took into account group differences in age, health status and baseline  
9 incontinence severity. The trial was not designed to measure the dose-response of  
10 knowledge acquisition and behaviour change on urinary symptom improvement. Thus  
11 only crude, dichotomous self-reported measures of behaviour change were collected  
12 and should be interpreted with caution.  
13  
14  
15  
16  
17  
18  
19

### 20 **Relevance to the discipline**

21 The value of continence promotion interventions likely reflects the delivery method as  
22 well as the quality of the content. Group interventions that deliver continence  
23 education, self-management information, or a combination of the two will improve  
24 incontinence symptoms in 59%, 41% and 66% of recipients, respectively. It is  
25 surprising that the self-management intervention alone was not associated with  
26 significant improvement compared to sham control in this trial. This can potentially  
27 be explained by the fact that continence education was completely omitted from the  
28 self-management workshop, whereas some information on bladder functioning was  
29 provided to participants during the initial work that tested the self-management tool.<sup>19</sup>  
30  
31  
32  
33  
34  
35  
36  
37

### 38 **Implications for practice**

39 Implementation of community-based programs that promote behavioural techniques  
40 as first-line management for incontinence support evidence for the superior efficacy  
41 and tolerability of conservative management approaches over pharmacological  
42 treatment for incontinence.[34] As “silent sufferers” become better informed that  
43 effective strategies exist for improving urinary symptoms, patient demand for care  
44 will likely increase. Almost 20% of women made an appointment to discuss urine  
45 leakage with a health professional in the three months following receipt of the  
46 continence education intervention. Evidence-based guidelines exist for physicians to  
47 evaluate and manage urinary incontinence when first-line behavioural strategies fail,  
48 and will need to be more frequently applied.[5,11]  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 In conclusion, continence education combined with self-management delivered via  
4 community organisations to untreated older women with incontinence leads to  
5 symptom improvement in 1 out of every 2 recipients. At the current time, the majority  
6 of older women with incontinence do not seek care, and either self-manage their  
7 symptoms inappropriately or use protection to palliate urine leakage.[1-4] As  
8 incontinence is associated with multimorbidity and other deleterious health effects,  
9 results from this trial provide strong justification for public health outreach via  
10 community organisations to reduce urine leakage among untreated individuals.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgments

We wish to acknowledge the assistance of Mira Jabbour and Francine Giroux for their expert help with database management and the data analyses. Nikki Cotterill, Adele Long aided with recruitment in the Bristol area. The above-mentioned individuals received financial compensation for their contribution to this work. We express gratitude to all the participants who took part in this trial. Although not exhaustive, particular thanks are offered to the following organisations and groups for participating in the trial: the Women's Institute, AGE UK, the University of the Third Age, Queens Nursing Institute (Scotland), Kinship Carers, the Women's Guild, Hanover Housing Association, Good Neighbours, Asian Carers Groups, Older Peoples Forum throughout the UK.

## Author Contribution Statement

Cara Tannenbaum designed the study and participated in the data analysis and interpretation. She wrote the first draft of the manuscript. Rona Agnew was responsible for data collection, participated in the data analysis and interpretation and critically reviewed the manuscript. Andrea Benedetti was responsible for the data analysis and interpretation and critically reviewed the manuscript. Doneal Thomas conducted the analyses and reviewed the manuscript. Eleanor van den Heuvel helped design the study, participated in the study implementation, helped interpret the findings and critically reviewed the manuscript.

## Data Access and Sharing Statement

Cara Tannenbaum, Doneal Thomas and Andrea Benedetti had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Patient level data and the full dataset is available upon request from the authors. Consent for data sharing was not obtained but the presented data are anonymised and the risk of identification is low.

## Competing interests

1  
2  
3 Cara Tannenbaum declares having been an advisory board member or received  
4 speaker honoraria from Pfizer, Watson, Astellas, Allergen and Ferring  
5 pharmaceuticals in the past 3 years, but not in relation to this work. All other authors  
6 declare: no support from any organisation for the submitted work; no financial  
7 relationships with any organisations that might have an interest in the submitted work  
8 in the previous three years, and no other relationships or activities that could appear to  
9 have influenced the submitted work.  
10  
11  
12  
13  
14

### 15 16 **Funding and Sponsor's Role** 17

18  
19 The trial was funded by a joint collaboration between the Canadian Institutes of  
20 Health Research and the Economic and Social Research Council (UK). The authors  
21 retained full independence from the study sponsors in the design and conduct of the  
22 study; collection, management, analysis, and interpretation of the data; preparation,  
23 review, and approval of the manuscript; and decision to submit the manuscript for  
24 publication.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## REFERENCES

1. Sexton CC, Coyne KS, Thompson C, et al. Prevalence and effect on health-related quality of life of overactive bladder in older Americans: Results from the Epidemiology of Lower Urinary Tract Symptoms Study. *J Am Geriatr Soc* 2011;**59**:1465–1470.
2. Tannenbaum C, Corcos J, Assalian P. The relationship between sexual activity and urinary incontinence in older women. *J Am Geriatr Soc* 2006;**54**:1220-4.
3. O'Donnell M, Lose G, Sykes D, et al. Help-seeking behaviour and associated factors among women with urinary incontinence in France, Germany, Spain and the United Kingdom. *Eur Urol* 2005;**47**:385-92
4. Herschorn S, Gajewski J, Schulz J, et al. A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey. *BJU Int* 2008;**101**:52-8.
5. Bland DR et al. The effects of implementation of the Agency for Health Care Policy and Research urinary incontinence guidelines in primary care. *J Am Geriatr Soc* 2003;**51**:979–984.
6. Subak LL, Wagner TH. Talking about incontinence: the first step toward prevention and treatment. *JAMA* 2010;**303**:2184-2185.
7. Tannenbaum C, Gray M, Hoffstetter S, et al. Comorbidities associated with bladder dysfunction. *Int J Clin Pract* 2013;**67**:105-13.
8. Farage MA, Miller KW, Berardesca E, et al. Psychosocial and societal burden of incontinence in the aged population. *Arch Gynecol Obstet* 2008;**277**:285-290.
9. Holroyd-Leduc JM, Mehta KM, Covinsky KE. Urinary incontinence and its association with death, nursing home admission, and functional decline. *J Am Geriatr Soc* 2004;**52**:712-8.
10. Chiarelli PE, Mackenzie LA, Osmotherly PG. Urinary incontinence is associated with an increase in falls: a systematic review. *Aust J Physiother* 2009;**55**:89-95.
11. Holroyd-Leduc JM, Tannenbaum C, Thorpe KE, et al. What type of urinary incontinence does this woman have? *JAMA* 2008;**299**:1446-56.
12. Goode PS, Burgio KL, Richter HE, et al. Incontinence in older women. *JAMA* 2010;**303**:2172-81.



13. Tannenbaum C, Bachand, G, DuBeau CE, et al. Experience of an incontinence clinic for older women : no apparent age limit for potential physical and psychological benefits. *J Women Health Gend Based Med* 2001;**10**:751-56.
14. Tannenbaum C, Brouillette J, Corcos J. Rating improvements in urinary incontinence: do patients and physicians agree? *Age Ageing* 2008;**37**:1-5
15. Newman DK, Buckley B, Gordon D et al. Continence promotion, education and primary prevention. In Abrams P, Cardozo L, Khoury S, Wein A eds: *Incontinence*. 5<sup>th</sup> International Consultation on Incontinence, Paris, February 2012. Health Publication Ltd 2013.
16. Agnew R, van den Heuvel E, Tannenbaum C. Efficiency of using community organisations as catalysts for recruitment to continence promotion trials. *Clin Trials* 2013;**10**:151-9.
17. Tannenbaum C, Drali R, Holroyd-Leduc J Richard L. Lessons learned: Impact of a continence promotion activity for older community dwelling women. *Neurourol Urodyn* 2010;**29**:540-544.
18. Wilde MH, Bliss DZ, Booth J, et al. Self-Management of Urinary and Fecal Incontinence. *AJN* 2013 in press.
19. Holroyd-Leduc J, Strauss S, Thorpe K, et al. Translation of evidence into a self-management tool for use by women with urinary incontinence. *Age Ageing* 2011;**40**:227-33.
20. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. *Am J Obstet Gynecol* 2003;**189**: 98–101.
21. Avery K, Donovan J, Peters TJ et al. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. *Neurourol Urodyn* 2004; **23**: 322–30.
22. Eldridge SM; Ashby D; Kerry S. Sample size for cluster randomised trials: effect of coefficient of variation of cluster size and analysis method. *Int J Epidemiol* 2006;**35**:1292-1300.
23. Ukoumunne OC, Forbes AB, Carlin JB, et al. Comparison of the risk difference, risk ratio and odds ratio scales for quantifying the unadjusted intervention effect in cluster randomised trials. *Stat Med* 2008;**27**: 5143-5155.
24. Users' guide to the medical literature. Integrating research evidence with the care of the individual patient. *JAMA* 2000;**283**:2829-2836.

25. Hanley JA, Negassa A, Edwardes MD. GEE analysis of negatively correlated binary responses: a caution. *Stat Med* 2000;**19**:715–722.
26. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;**337**:979-983.
27. Campbell MK, Piaggio G, Elbourne DR, et al. Consort 2010 statement: extension to cluster randomised trials. *BMJ* 2012;**345**:e5661.
28. Kincade JE, Dougherty MC, Carlson JR, et al. Randomised clinical trial of efficacy of self-monitoring techniques to treat urinary incontinence in women. *Neurourol Urodyn* 2007;**26**:507-11.
29. Wagg AR, Barron D, Kirby M, et al. A randomised partially controlled trial to assess the impact of self-help vs. structured help from a continence nurse specialist in women with undiagnosed urinary problems in primary care. *Int J Clin Pract* 2007;**61**:1863-73.
30. Dougherty MC, Dwyer JW, Pendergast JF et al. A randomised trial of behavioral management for continence with older rural women. *Res Nurs Health* 2002;**25**:3-13.
31. McFall SL, Yerkes AM, Cowan LD. Outcomes of a small group educational intervention for urinary incontinence: episodes of incontinence and other urinary symptoms. *J Aging Health* 2000;**12**:250-67.
32. Milne J. The impact of information on health behaviors of older adults with urinary incontinence. *Clin Nurs Res* 2000;**9**:161-76.
33. Goode PS, Burgio KL, Locher JL et al. Effect of behavioral training with or without pelvic floor electrical stimulation on stress incontinence in women: a randomized controlled trial. *JAMA* 2003;**290**(3):345-52.
34. Shamliyan T, Wyman J, Kane RL. Nonsurgical treatments for urinary incontinence in adult women: diagnosis and comparative effectiveness. Comparative Effectiveness Review No. 36. (Prepared by the University of Minnesota Evidence-based Practice Center under Contract No. HHSA 290-2007-10064-I.) AHRQ Publication No. 11(12)-EHC074-EF. Rockville, MD. Agency for Healthcare Research and Quality. April 2012. Available at: [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm).

Table 1: Baseline characteristics and distribution of modifiable risk factors of participants

	Continence education (n=64)	Self-management (n=70)	Combined intervention (n=61)	Control intervention (n=64)
	<b>Mean ± SD</b>			
Age	70.8 ± 7.9	71.0 ± 6.8	70.4 ± 6.7	74.1 ± 8.1
Mean ICIQ score*	8.5 ± 4.4	6.8 ± 3	7.3 ± 5.6	6.7 ± 3.4
	<b>(% yes)</b>			
Lives alone	48.4	40.0	37.7	59.4
Education				
University degree or equivalent	31.2	45.7	37.7	19.0
General health perception				
Good, very good, excellent	53.1	85.7	80.3	75.0
Fair/poor	45.3	14.3	16.4	25.0
Depression	48.4	35.7	32.8	20.3
Heart disease	35.9	25.7	16.4	21.0
Falls	45.3	31.4	18.0	18.8
Arthritis	78.1	52.9	44.3	57.8
Diabetes	39.1	24.3	18.0	20.3
High blood pressure	59.0	40.0	45.9	55.6
<b>Type of incontinence</b>				
Stress only	15.6	12.9	14.8	33.3
Urgency only	32.8	35.7	29.5	20.6
Mixed	45.3	42.9	55.7	39.7
<b>Modifiable risk factors</b>				
Performs pelvic floor muscle exercises 3 times per week	18.8	15.7	11.9	15.6
Self-reported body mass index $\geq 27 \text{ kg/m}^2$ **	53.2	53.0	42.4	49.2
Drinks more than 1.5 litres of fluid/day	43.8	44.3	54.1	37.5
Drinks one cup of tea or more/day	85.9	84.3	73.8	84.4
Drinks one cup of coffee or more/day	46.9	62.9	65.6	64.1
Smokes	6.3	4.3	4.9	6.2

\*ICIQ = International Consultation on Incontinence Questionnaire, used to measure the severity and bother from urinary incontinence. Scores range from 0 to 21, with higher scores representing worse incontinence.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

\*\*Self-reported body mass index: calculated as weight (kg)/height<sup>2</sup> (m) based on participant's self-reported height and weight at baseline

For peer review only

Table 2: Prevalence, risk difference and odds ratios for self-reported improvements in incontinence at 3-months

	Prevalence at 3-month follow-up				Prevalence difference (95% CI)*			Odds ratio (95% CI)					
	Conti- nence	SM	Combined	Control	Continen- ce vs control	SM vs control	Combined vs control	Crude			Adjusted**		
								Continen- ce vs control	SM vs control	Combined vs control	Conti- nence vs control	SM vs control	Combined vs control
<b>Any improvement</b>													
Intention-to- treat	0.59	0.41	0.66	0.11	0.48 (0.33-0.64)	0.28 (0.08- 0.48)	.55 (0.43- 0.67)	11.72 (4.54- 30.21)	5.16 (1.73- 15.37)	15.51 (6.50- 37.01)	9.14 (3.05- 27.37)	2.71 (0.87- 8.41)	17.63 (5.09- 61.13)
Per protocol	0.64	0.47	0.73	0.13	0.51 (0.34- 0.67)	0.29 (0.07- 0.51)	0.59 (0.45- 0.74)	11.45 (4.27- 30.67)	4.64 (1.48- 14.56)	17.14 (6.51- 45.11)	10.40 (3.05- 35.48)	3.46 (1.08- 11.03)	23.27 (5.91- 91.59)
ICC Intention-to- treat	-	-	-	-	0.02	0.18	0	0.24	0.18	0	0	0.06	0
ICC per protocol	-	-	-	-	0.03	0.25	0	0.03	0.25	0	0	0.14	0
<b>Very much better or much better</b>													
Intention-to- treat	0.22	0.21	0.30	0.06	0.16 (0.03- 0.29)	0.14 (0.01- 0.27)	0.23 (0.10- 0.36)	4.2 (1.4-13.0)	3.8 (1.2-12.2)	6.3 (2.2- 17.7)	2.83 (0.59- 13.66)	1.81 (0.50- 6.60)	4.94 (1.45- 16.86)

Per protocol	0.24	0.24	0.33	0.08	0.16 (0.02- 0.30)	0.15 (0.00- 0.29)	0.26 (0.10- 0.42)	3.7 (1.2- 11.3)	3.5 (1.06- 11.31)	5.8 (2.0-17.4)	2.51 (0.48- 13.18)	2.28 (0.63- 8.24)	5.32 (1.39- 20.34)
ICC Intention-to- treat	-	-	-	-	0.02	0.06	0	0.02	0.06	0	0	0	0
ICC per protocol	-	-	-	-	0.01	0.08	0.02	0.01	0.08	0	0	0.02	0

SM = Self-management; ICC = intra-cluster correlation correlation

\*95% CI's were calculated using robust standard errors

\*\*Adjusted for age, living alone, depression, heart disease, falls, arthritis, diabetes, high blood pressure, educational status, general health perception, and baseline incontinence severity score

Table 3: Change in incontinence-related knowledge

		Continence education n=64	Self-management n=70	Combined intervention n=61	Control n=64
1. Urinary incontinence is a normal part of ageing	Baseline % agreement	73.0	79.7	77.0	79.7
	3 month follow up % agreement	36.2	63.9	38.2	82.7
	p value for change*	<b>&lt;0.001</b>	<b>0.02</b>	<b>&lt;0.001</b>	0.73
2. Once people start to leak urine, they are never able to control their urine again	Baseline % agreement	41.9	32.9	36.1	50.8
	3 month follow up % agreement	29.3	17.7	7.3	51.9
	p value for change	0.12	0.06	<b>&lt;0.001</b>	1
3. Urine leakage can be caused by many different things	Baseline % agreement	88.9	92.8	88.3	86.9
	3 month follow up % agreement	93.1	88.7	92.7	90.4
	p value for change	1	0.77	0.73	0.63
4. Wearing pads or diapers is the best way to manage urinary incontinence	Baseline % agreement	57.1	40.6	52.5	67.2
	3 month follow up % agreement	36.8	33.9	27.3	69.2
	p value for change	<b>0.03</b>	0.11	<b>0.001</b>	1
5. What you drink can contribute to urine leakage	Baseline % agreement	64.5	66.7	68.3	66.1
	3 month follow up % agreement	77.6	75.8	89.1	68.6

		Continence education n=64	Self- management n=70	Combined intervention n=61	Control n=64
	p value for change	0.26	0.36	<b>0.01</b>	0.77
6. How much you drink can contribute to urine leakage	Baseline % agreement	72.6	65.2	67.2	71.4
	3 month follow up % agreement	77.6	71	76.4	65.4
	p value for change	0.63	0.65	0.36	0.79
7. Losing weight can lead to improvement in incontinence	Baseline % agreement	61.3	74.3	66.1	75
	3 month follow up % agreement	77.6	77.4	90.9	80.8
	p value for change	0.08	0.69	<b>&lt;0.001</b>	0.48
8. Exercising pelvic floor muscles can help control urine leakage	Baseline % agreement	85.5	88.6	85.2	96.9
	3 month follow up % agreement	96.5	96.7	98.2	98.1
	p value for change	<b>0.04</b>	0.13	<b>0.02</b>	1.0

\* McNemar's test for matched-pairs data



Effectiveness of continence promotion for older women via community organisations:  
a cluster randomised trial

Cara Tannenbaum, MD, MSc<sup>1</sup> Rona Agnew, PhD<sup>2</sup> Andrea Benedetti, PhD<sup>3</sup> Doneal  
Thomas, MSc<sup>4</sup> Eleanor van den Heuvel, PhD<sup>5</sup>

<sup>1</sup>Associate Professor, Faculty of Medicine, Université de Montréal, Quebec, Canada

<sup>2</sup>Clinical Research Fellow, Glasgow Caledonian University, Glasgow, UK

<sup>3</sup>Associate Professor, Departments of Medicine and of Epidemiology, Biostatistics &  
Occupational Health, McGill University, Quebec, Canada

<sup>4</sup>PhD candidate, Department of Epidemiology, Biostatistics & Occupational Health,  
McGill University, Quebec, Canada

<sup>5</sup>Director of Assistive Technology Programme, Brunel Institute for Ageing Studies,  
Brunel University, Uxbridge, UK

Word count : 3182

Key words: Continence promotion, cluster trial, community organisations, older  
women, urinary incontinence

Corresponding Author: Dr. Cara Tannenbaum, Centre de Recherche de l'Institut  
universitaire de gériatrie de Montréal, 4545 Queen Mary Road, Montreal, Quebec,  
Canada H3W 1W5. Tel (514) 340-2800. Fax : (514) 340-3530.

Email: [cara.tannenbaum@umontreal.ca](mailto:cara.tannenbaum@umontreal.ca)

The Corresponding Author has the right to grant on behalf of all authors and does  
grant on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ  
Publishing Group Ltd to permit this article (if accepted) to be published in BMJ Open  
editions and any other BMJ PGL products and sublicences such use and exploit all  
subsidiary rights, as set out in the licence.

1  
2  
3 All authors have completed the Unified Competing Interest form at  
4 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding  
5 author) and declare: no support from any organisation for the submitted work; no  
6 financial relationships with any organisations that might have an interest in the  
7 submitted work in the previous three years, and no other relationships or activities that  
8 could appear to have influenced the submitted work.  
9  
10  
11  
12

13  
14  
15 The authors retained full independence from the study sponsors in the design,  
16 implementation, analysis, interpretation and reporting of the findings.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objectives:** The primary objective of this cluster randomised controlled trial was to compare the effectiveness of the three experimental continence promotion interventions against a control intervention on urinary symptom improvement in older women with untreated incontinence recruited from community organisations. A second objective was to determine whether changes in incontinence-related knowledge and new uptake of risk-modifying behaviours explain these improvements.

**Setting:** 71 community organisations across the United Kingdom

**Participants:** 259 women aged 60 years and older with untreated incontinence entered the trial; 88% completed the 3-month follow-up.

**Interventions:** The three active interventions consisted of a single 60-minute group workshop on 1) continence education (20 clusters, 64 women); 2) evidence-based self-management (17 clusters, 70 women); or 3) combined continence education and self-management (17 clusters, 61 women). The control intervention was a single 60-minute educational group workshop on memory loss, polypharmacy and osteoporosis (17 clusters, 64 women).

**Primary and secondary outcome measures:** The primary outcome was self-reported improvement in incontinence 3 months post-intervention at the level of the individual.

The secondary outcome was change in the International Consultation on Incontinence Questionnaire (ICIQ) from baseline to 3-month follow-up. Changes in incontinence-related knowledge and behaviours were also assessed.

**Results:** The highest rate of urinary symptom improvement occurred in the combined intervention group (66% vs 11% of the control group, prevalence difference 55%, 95% CI 43%-67%, intraclass correlation 0). Thirty percent versus 6% of participants reported significant improvement respectively (prevalence difference 23%, 95% CI 10%-36%, intraclass correlation 0). The number-needed-to-treat was 2 to achieve any improvement in incontinence symptoms, and 5 to attain significant improvement.

Compared to controls, participants in the combined intervention reported an adjusted

1  
2  
3 mean 2.05 point (95% CI 0.87-3.24) greater improvement on the ICIQ from baseline  
4 to 3-month follow up. Changes in knowledge and self-reported risk-reduction  
5 behaviours paralleled rates of improvement in all intervention arms.  
6  
7  
8

9  
10 **Conclusion:** Continence education combined with evidence-based self-management  
11 improves symptoms of incontinence among untreated older women. Community  
12 organisations represent an untapped vector for delivering effective continence  
13 promotion interventions.  
14  
15

16  
17  
18 **Trial registration:** ClinicalTrials.gov ID number NCT01239836  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Article Summary : Strengths and limitations of this study

- First study to provide Level 1 evidence that continence promotion is an effective strategy for improving urinary symptoms among untreated community-dwelling older women
- Participants were recruited via community organisations with representation across diverse socio-economic strata
- Rates of knowledge acquisition and behaviour change provide an explanatory mechanism for the observed improvements in incontinence in participants receiving the combined education plus self-management strategy
- Only self-reported outcomes and crude dichotomous measures of behaviour change were collected so results must be interpreted with caution

## Introduction

Urinary incontinence is more frequent than breast cancer, heart disease or diabetes among older women, but remains a stigmatized and untreated condition despite its high prevalence. [1-4] In the United States, Canada, the U.K. and other European countries, up to 40% of women aged 65 years and older experience involuntary urine leakage, but little more than 15-30% seek care.[1-4] Even fewer physicians feel competent evaluating or treating incontinence.[5-6] Urinary incontinence is associated with obesity, cardiovascular disease, diabetes, depression, social isolation, decline in function, falls, nursing home admission, and onerous out-of-pocket expenses.[6-10] In many cases incontinence can be improved, and even cured, when evidence-based diagnostic and treatment strategies are appropriately applied.[6,11-14]

It is a commonly held misconception that incontinence is a normal part of aging.[15] Not-for-profit organisations seek to raise continence awareness worldwide and promote treatment for incontinent individuals. Media campaigns, brochures and public awareness lectures attempt to de-stigmatise incontinence and increase help-seeking, but the effectiveness of these initiatives for reaching their target population remains unknown.[15] Transmission of public health education via community organisations is an unexplored strategy for improving urinary symptoms.[16] Data from randomised trials are needed to determine whether the delivery of an evidence-based continence intervention via community organisations is an effective method for treating incontinence.

The primary objective of this cluster randomised controlled trial was to compare the effectiveness of the three experimental continence promotion interventions against a control intervention on urinary symptom improvement in older women with untreated incontinence recruited from community organisations. A second objective was to determine whether changes in incontinence-related knowledge, attitudes and new uptake of risk-modifying behaviours explain improvements in incontinence. We hypothesized that continence education combined with evidence-based self-management would yield the greatest improvement in incontinence symptoms, measured at the level of the individual, 3-months post-intervention.

## METHODS

### Study design and oversight

A 4 arm, parallel-group, controlled, cluster randomised trial was conducted. The study design, recruitment methods and interventions have been reported.[16] Clustering was at the level of the community organisation, from whence participants were recruited. The choice of a cluster design served to prevent contamination between participants in the same community organisation. The trial was designed by two of the authors and was overseen by the full investigator team, which had full access to the data. The data were collected at community organisations across the United Kingdom. All participants provided written informed consent. The protocol was approved by the Brunel University Research Ethics Committee.

### Study population and recruitment

Inclusion criteria for community organisations included any organisation throughout the United Kingdom that consented to participate in the trial between November 2010 and September 2012. A community organisation was loosely defined as any not-for-profit group of individuals with a shared interest. These included interest and charity groups, seniors' housing groups, women's lobby groups and Asian caregiver associations.[16] Organisations were contacted strategically by convenience sampling, word of mouth and referral. A research coordinator approached community organisations to join the trial by telephone, email and newspaper advertising.

Inclusion criteria for participants were women aged 60 years and older who reported urinary incontinence at least once weekly on the International Consultation on Incontinence Questionnaire (ICIQ), and who were not under active treatment for incontinence. For privacy reasons, many community organisations were uncomfortable screening their members for incontinence in advance, so eligibility to participate in the trial could only be ascertained by the research coordinator on the day of delivery of the intervention.[16] Eligibility to participate in the trial was established by asking all attendees at the workshop to complete a baseline screening questionnaire upon arrival. At this time, a study information sheet and consent form were distributed to all participants. All women, regardless of eligibility or desire to enrol in

1  
2  
3 the trial, were permitted to stay for the workshop. Only those women who wished to  
4 enrol in the trial submitted the signed consent form to the workshop facilitator  
5 following delivery of the intervention, however all attendees were encouraged to  
6 submit the baseline screening questionnaire even if they were continent or did not  
7 wish to participate in the trial.  
8  
9  
10

### 11 12 13 **Interventions**

14  
15  
16 The interventions were applied at the level of each cluster. The three experimental  
17 interventions to be tested were continence education, self-management including the  
18 distribution of an evidence-based risk factor reduction tool for incontinence, and a  
19 combined intervention that included both components. The sham control intervention  
20 was a lecture on health promotion for older women that addressed topics other than  
21 incontinence. All interventions were delivered once in group format to 8-16 women  
22 by the same facilitator at a venue of the organisation's choosing, and lasted 60-90  
23 minutes. A slide presentation with a pre-established script prepared for the facilitator  
24 was delivered at each workshop.  
25  
26  
27  
28  
29  
30  
31

32  
33 The continence promotion intervention incorporated elements of constructivist  
34 learning that challenged older adults' erroneous beliefs about accepting incontinence  
35 as a normal part of aging, and aimed to change attitudes and create new knowledge  
36 about the different types, etiology, risk factors and treatment options for urine  
37 loss.[16-17] The self-management workshop reviewed self-management theory in an  
38 interactive format, and provided a customised evidence-based self-management  
39 program for risk factor modification for incontinence to each participant.[18-19] The  
40 program targeted pelvic floor muscle weakness, obesity, consumption of caffeinated  
41 beverages, smoking, vision loss and constipation, with instructions on how to keep a  
42 bladder diary to help monitor symptoms. The content of the combined intervention  
43 condensed elements from the continence promotion workshop along with self-  
44 management theory, and provided the customized self-management tool to  
45 participants. The control intervention addressed other non-bladder related aspects of  
46 older women's health such as memory problems, polypharmacy, osteoporosis,  
47 nutrition, physical fitness and vision impairment.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Study Outcomes

The primary outcome was the participant's global impression of improvement in incontinence symptoms, measured at 3 months post-intervention by telephone interview using the patient's global impression of improvement (PGI-I) questionnaire. The PGI-I is a validated, single-item global rating of change scale that asks the patient to describe how their incontinence condition is now compared to how it was prior to the intervention (very much better, much better, a little bit better, no change, a little bit worse, much worse and very much worse).[20] The primary outcome, any improvement, was defined as a rating of a little bit better, much better or very much better. A secondary outcome, significant improvement, was defined as much better or very much better. The ICIQ, which measures the frequency, severity and bother from incontinence was used at baseline to screen participants for inclusion to the trial, and was repeated at follow-up.[21] The ICIQ diagnostic item was used by participants to describe the type of incontinence at baseline. A pre- and post-8-item questionnaire on knowledge and attitudes towards incontinence was administered at baseline and at 3-month follow-up, as were risk factors and behaviors related to incontinence.[17] Risk factors and behaviors included performance of pelvic floor muscle exercises three times weekly (yes, no), daily consumption of 1 cup or more of tea or coffee (yes, no), fluid intake > 1.5 L/day (yes, no), weight and height (self-report) and smoking status (yes, no). At three month follow-up participants were asked whether they had sought treatment for urine leakage during the past 3 months. All follow-up interviews were performed by the research coordinator, who was blinded to participant identification.

The original study protocol sought to examine reductions in urinary frequency as measured on a bladder diary and reductions in the cost of pad use as primary and secondary outcomes respectively. However as soon as recruitment for the trial commenced it became apparent that distribution of bladder diaries and objective measurement of pad use pre-intervention would not be possible. This occurred as a result of privacy concerns expressed by participating community organisations for revealing and sharing their members' names and contact information with the research team prior to the delivery of the workshops.[16] The PGI-I was therefore used as the revised primary measure of effectiveness from the onset of the trial. Data on self-efficacy for managing incontinence was also collected, but is not reported in

1  
2  
3 this paper due to problems with comprehension of the visual analogue response scale  
4 during the 3-month telephone follow-up that occurred non-differentially among  
5 participants in all arms of the study.  
6  
7  
8  
9

### 10 **Randomisation and allocation concealment**

11 Group allocation occurred by non-stratified randomisation in blocked groups of 4 of  
12 consenting organisations that agreed to host a workshop. An independent statistician  
13 at a distant study site was responsible for randomisation using computer-generated  
14 random digits. Community organisations were informed that one of four workshops  
15 would be delivered on health topics of interest to older women, but not which one. In  
16 this way, group allocation was concealed from both the clusters and the individual  
17 participants, who were invited by the host organisation to attend a “Women’s Health  
18 Workshop”. The research coordinator remained unaware of group allocation at the  
19 time each community organisation was recruited to the trial because she was only  
20 informed which workshop to prepare for each organisation several days before each  
21 workshop. The trial is considered open-label because both the research facilitator who  
22 delivered the intervention and the participants who received it were aware of which  
23 intervention was being delivered.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

### 35 **Sample Size**

36 The trial was designed to detect a minimal 35% difference in the number of  
37 participants reporting any improvement (very much better, much better, a little bit  
38 better on the PGI-I) between the experimental and control conditions, assuming a rate  
39 of improvement in the control condition as high as 20%, with 80% power and alpha  
40 0.05 two-sided (n=34). Using an inflation factor of 1.65 to account for an anticipated  
41 maximum intracluster correlation (ICC) of 0.05 and unequal cluster size yielded a  
42 recruitment target of 56 participants per group.[22]  
43  
44  
45  
46  
47  
48  
49

### 50 **Statistical Methods**

51 Differences in baseline characteristics between the four groups were determined. To  
52 assess the primary outcome we estimated the unadjusted risk difference (prevalence  
53 of the outcome) and 95% confidence intervals (CI) via generalized estimating  
54 equations (GEEs) for participants who reported any improvement on the PGI-I. We  
55 repeated the same analysis for those who reported significant improvement. GEEs  
56  
57  
58  
59  
60

1  
2  
3 with an identity link and an exchangeable correlation structure were used to account  
4 for possible correlation between women in the same organisation.[23] To adjust for  
5 the imbalance in potential confounders in the groups at baseline, additional analyses  
6 were conducted using multivariable logistic regression estimated via GEE with an  
7 exchangeable correlation structure. Potential confounders included age and baseline  
8 incontinence severity (ICIQ score) as continuous predictors, and living alone,  
9 depression, heart disease, falls, arthritis, diabetes, high blood pressure, educational  
10 status and general health perception as dichotomous predictors. Both intent-to-treat  
11 (ITT) and per protocol (PP) analyses were performed. For the ITT analysis,  
12 participants with missing data were assumed to have no change in incontinence status  
13 at three-month follow-up. The number needed to treat was calculated as the inverse of  
14 the difference in absolute event rates between the experimental and control  
15 groups.[24] We report intra-cluster (intra-community organisation) correlation  
16 coefficients (ICC) from the marginal model using GEE with assumed exchangeable  
17 correlation structure and robust standard errors.[25] In cases where an ICC<0 was  
18 detected, we assumed a correlation structure of independence, but still used the  
19 robust variance estimator. The robust variance estimator is robust to misspecification  
20 of the correlation structure, so standard errors, confidence intervals and p values are  
21 still correct. To estimate adjusted mean group differences in ICIQ scores from  
22 baseline to 3-month follow up, we used GEE with a Gaussian regression model for  
23 continuous outcomes and followed the same procedure outlined above.

24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40 Improvements in incontinence-related knowledge by intervention type for proportions  
41 of individuals responding correctly to each knowledge questionnaire item at baseline  
42 compared to 3-month follow-up were estimated using McNemar's test for matched  
43 pair analysis. Rates of improvement in self-reported risk modifying behaviours for  
44 incontinence were calculated, along with 95% confidence intervals. Differences in  
45 improvement rates between the intervention and the control group were compared  
46 using Fisher's Exact test using a per protocol analysis. A difference in response for  
47 each health behavior item that indicated adoption of a new risk modifying behaviour  
48 was defined as a positive change at 3-month follow-up compared to baseline.

49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Reduced coffee and tea intake refer to individuals who reduced their consumption to a  
single cup per day or less. Weight loss was determined by a positive response to the  
question, "Has your weight changed (yes, no) and if so, how much do you now

weigh?" and evidence of self-reported current weight lower than self-reported weight at baseline. All statistical analyses were run using RStudio 0.97.310.0, an integrated development environment for R.

## RESULTS

### Study participants and follow-up

Four-hundred-and-twenty different community organisations were approached over an 18-month period to participate in the trial. Of these, 17% consented and succeeded in hosting an intervention, yielding 71 clusters that were randomised. Approximately one quarter of the groups contacted refused; 2% expressed interest but were unable to organise a workshop; and a little over half failed to give any response although most of them had been followed up and had received extra information on the project.<sup>16</sup> Figure 1 depicts the study flow of the clusters and participants through the trial. Seven-hundred-and-sixty three women attended the workshops, of whom 322 (42%) were known to be eligible for the trial. The mean number of participants recruited from each cluster for the continence promotion group was  $3 \pm 2$ , whereas it was  $4 \pm 2$  for the other 3 groups. Eighty-percent (259/322) of known eligible attendees to the workshops consented to take part in the trial. Two-hundred-and-twenty-eight of these (88%) were available for 3-month follow-up. Table 1 compares the baseline characteristics of participants in each trial arm.

### Primary and secondary outcomes

The highest rate of improvement in incontinence occurred in the combined intervention group, 66% compared to 11% in the control group (prevalence difference 55%, 95% CI 43%-67%), yielding a number-needed-to-treat of 2. Thirty percent of the combined group reported significant improvement compared to 6% of controls (prevalence difference 23%, 95% CI 10%-36%, number-needed-to-treat of 5). In adjusted analyses, the likelihood of achieving a significant improvement in urinary symptoms from exposure to the combined intervention was five times greater than exposure to the control intervention (OR 4.94, 95% CI 1.45-16.86). Compared to controls, the participants in the combined intervention reported an adjusted mean 2.05 point (95% CI 0.87-3.24) greater improvement on the ICIQ from baseline to 3-month follow up. The adjusted mean difference in ICIQ scores was also significantly higher

1  
2  
3 for the continence education group compared to the control group (1.33 point greater  
4 improvement (95% CI 0.33-2.32)), but not for the self-management group. The per  
5 protocol analysis for the primary outcome and the intra-cluster correlation coefficients  
6 for each analysis are shown in Table 2.  
7  
8  
9

### 11 **Other outcomes**

12 Table 3 shows the changes in incontinence-related knowledge attributable to receipt  
13 of each intervention. Participants exposed to the combined intervention showed the  
14 greatest acquisition in knowledge, exhibiting significant within-group improvement  
15 on 6 out of 8 questionnaire items. Participants learned that incontinence is not an  
16 inevitable or irreversible part of aging, that losing weight, changing the type of fluid  
17 intake and performing pelvic floor muscle exercises can reduce urinary symptoms,  
18 and that wearing undergarment protection is not always the best way to manage  
19 incontinence.  
20  
21  
22  
23  
24  
25  
26  
27

28 The proportion of participants with modifiable risk factors for incontinence in each  
29 group at baseline is shown in Table 1. The adoption of various risk-modifying  
30 behaviours among participants occurred to a different degree as a result of exposure to  
31 all three experimental but not the control intervention (Figure 2). At three-month  
32 follow-up, the proportion of women reporting uptake of pelvic floor muscle exercises  
33 and weight loss was significantly higher in the continence education group (46% and  
34 20% respectively), the self-management group (34% and 20%) and the combined  
35 intervention group (53% and 18%) compared to controls (8% and 3%). Many women  
36 additionally reduced their coffee intake and total fluid intake. The proportion of  
37 women who made an appointment to consult a health professional for urine leakage  
38 was 19% in the continence promotion group, 7% in the self-management group, 16%  
39 in the combined intervention group and 4% in the control group.  
40  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **DISCUSSION**

50  
51  
52 In this cluster-randomised trial testing the effectiveness of 3 different continence  
53 promotion interventions, we found that health education combined with the delivery  
54 of an evidence-based self-management tool via community organisations to untreated  
55 older women yielded the highest rate of urinary symptom improvement in 66% of  
56  
57  
58  
59  
60

1  
2  
3 recipients, half of whom reported significant improvements in incontinence. These  
4 outcomes translate into a number-needed-to-treat of 2 and 5 respectively, a magnitude  
5 of effect rarely achieved during public health interventions. Both new knowledge  
6 acquisition and the adoption of risk-modifying behaviours such as exercise and  
7 weight loss occurred as a result of community organisations' involvement in reaching  
8 untreated incontinent women outside the health care system.  
9  
10  
11  
12

### 13 14 15 **Strengths and weaknesses of the study**

16  
17 This is the first randomised trial to test the effectiveness of continence promotion  
18 strategies through community outreach. Both explanatory mechanisms and final  
19 health outcomes were assessed, and the use of a cluster randomised design was  
20 chosen to avoid contamination of the control group.[26,27] Our choice of comparator  
21 controlled for the placebo effect of participating in a group intervention. Breaches in  
22 the fidelity and quality of implementation of the intervention were minimized by  
23 having the same facilitator deliver each intervention. Improvements in urinary  
24 symptoms were shown with two validated measures, the PGI-I and the ICIQ. We  
25 believe the results have wide external validity as the community groups included  
26 women with varied educational levels and wide socioeconomic status.  
27  
28  
29  
30  
31  
32  
33  
34

35  
36 The results of this study confirm findings from previous randomised trials suggesting  
37 a positive effect of continence education and self-monitoring strategies on urinary  
38 symptom improvement in untreated incontinent individuals.[28-33] However all  
39 previous trials invited participants for clinical assessments prior to the delivery of the  
40 intervention, or involved individualized education sessions. The current trial delivered  
41 group continence interventions without medical or nursing evaluations, in a true  
42 public health approach, to both continent and incontinent women as part of the regular  
43 activities offered by each community organisation. Rates of improvement reported in  
44 this trial on the PGI-I were similar to or exceeded those reported in other studies using  
45 self-help booklets, in the range of 50%. **Because of the nature of recruitment and  
46 delivery of the intervention via community organisations, bladder diaries and pad tests  
47 could not be collected pre-intervention. The results of our trial can therefore not be  
48 directly compared to other trials that used more objective measures of symptom  
49 improvement.**  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Other limitations apply. Due to the nature of recruiting potential participants, individuals could not be screened and enrolled in the trial prior to randomisation of the clusters.[27] The result was an imbalance between groups, accounted for by analyses that took into account group differences in age, health status and baseline incontinence severity. The trial was not designed to measure the dose-response of knowledge acquisition and behaviour change on urinary symptom improvement. Thus only crude, dichotomous self-reported measures of behaviour change were collected and should be interpreted with caution.

### **Relevance to the discipline**

The value of continence promotion interventions likely reflects the delivery method as well as the quality of the content. Group interventions that deliver continence education, self-management information, or a combination of the two will improve incontinence symptoms in 59%, 41% and 66% of recipients, respectively. It is surprising that the self-management intervention alone was not associated with significant improvement compared to sham control in this trial. This can potentially be explained by the fact that continence education was completely omitted from the self-management workshop, whereas some information on bladder functioning was provided to participants during the initial work that tested the self-management tool.<sup>19</sup>

### **Implications for practice**

Implementation of community-based programs that promote behavioural techniques as first-line management for incontinence support evidence for the superior efficacy and tolerability of conservative management approaches over pharmacological treatment for incontinence.[34] As “silent sufferers” become better informed that effective strategies exist for improving urinary symptoms, patient demand for care will likely increase. Almost 20% of women made an appointment to discuss urine leakage with a health professional in the three months following receipt of the continence education intervention. Evidence-based guidelines exist for physicians to evaluate and manage urinary incontinence when first-line behavioural strategies fail, and will need to be more frequently applied.[5,11]

1  
2  
3 In conclusion, continence education combined with self-management delivered via  
4 community organisations to untreated older women with incontinence leads to  
5 symptom improvement in 1 out of every 2 recipients. At the current time, the majority  
6 of older women with incontinence do not seek care, and either self-manage their  
7 symptoms inappropriately or use protection to palliate urine leakage.[1-4] As  
8 incontinence is associated with multimorbidity and other deleterious health effects,  
9 results from this trial provide strong justification for public health outreach via  
10 community organisations to reduce urine leakage among untreated individuals.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Acknowledgments

We wish to acknowledge the assistance of Mira Jabbour and Francine Giroux for their expert help with database management and the data analyses. Nikki Cotterill, Adele Long aided with recruitment in the Bristol area. The above-mentioned individuals received financial compensation for their contribution to this work. We express gratitude to all the participants who took part in this trial. Although not exhaustive, particular thanks are offered to the following organisations and groups for participating in the trial: the Women's Institute, AGE UK, the University of the Third Age, Queens Nursing Institute (Scotland), Kinship Carers, the Women's Guild, Hanover Housing Association, Good Neighbours, Asian Carers Groups, Older Peoples Forum throughout the UK.

## Author Contribution Statement

Cara Tannenbaum designed the study and participated in the data analysis and interpretation. She wrote the first draft of the manuscript. Rona Agnew was responsible for data collection, participated in the data analysis and interpretation and critically reviewed the manuscript. Andrea Benedetti was responsible for the data analysis and interpretation and critically reviewed the manuscript. Doneal Thomas conducted the analyses and reviewed the manuscript. Eleanor van den Heuvel helped design the study, participated in the study implementation, helped interpret the findings and critically reviewed the manuscript.

## Data Access and Sharing Statement

Cara Tannenbaum, Doneal Thomas and Andrea Benedetti had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Patient level data and the full dataset is available upon request from the authors. Consent for data sharing was not obtained but the presented data are anonymised and the risk of identification is low.

## Competing interests

1  
2  
3 Cara Tannenbaum declares having been an advisory board member or received  
4 speaker honoraria from Pfizer, Watson, Astellas, Allergan and Ferring  
5 pharmaceuticals in the past 3 years, but not in relation to this work. All other authors  
6 declare: no support from any organisation for the submitted work; no financial  
7 relationships with any organisations that might have an interest in the submitted work  
8 in the previous three years, and no other relationships or activities that could appear to  
9 have influenced the submitted work.  
10  
11  
12  
13

### 14 15 16 **Funding and Sponsor's Role** 17

18  
19 The trial was funded by a joint collaboration between the Canadian Institutes of  
20 Health Research and the Economic and Social Research Council (UK). The authors  
21 retained full independence from the study sponsors in the design and conduct of the  
22 study; collection, management, analysis, and interpretation of the data; preparation,  
23 review, and approval of the manuscript; and decision to submit the manuscript for  
24 publication.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Sexton CC, Coyne KS, Thompson C, Bavendam T, Chen CI, Markland A. Prevalence and effect on health-related quality of life of overactive bladder in older Americans: Results from the Epidemiology of Lower Urinary Tract Symptoms Study. *J Am Geriatr Soc* 2011;**59**:1465–1470.
2. Tannenbaum C, Corcos J, Assalian P. The relationship between sexual activity and urinary incontinence in older women. *J Am Geriatr Soc* 2006;**54**:1220-4.
3. O'Donnell M, Lose G, Sykes D, Voss S, Hunskaar S. Help-seeking behaviour and associated factors among women with urinary incontinence in France, Germany, Spain and the United Kingdom. *Eur Urol* 2005;**47**:385-92
4. Herschorn S, Gajewski J, Schulz J, Corcos J. A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey. *BJU Int* 2008;**101**:52-8.
5. Bland DR et al. The effects of implementation of the Agency for Health Care Policy and Research urinary incontinence guidelines in primary care. *J Am Geriatr Soc* 2003;**51**:979–984.
6. Subak LL, Wagner TH. Talking about incontinence: the first step toward prevention and treatment. *JAMA* 2010;**303**:2184-2185.
7. Tannenbaum C, Gray M, Hoffstetter S, Cardozo L. Comorbidities associated with bladder dysfunction. *Int J Clin Pract* 2013;**67**:105-13.
8. Farage MA, Miller KW, Berardesca E, Maibach HI. Psychosocial and societal burden of incontinence in the aged population. *Arch Gynecol Obstet* 2008;**277**:285-290.
9. Holroyd-Leduc JM, Mehta KM, Covinsky KE. Urinary incontinence and its association with death, nursing home admission, and functional decline. *J Am Geriatr Soc* 2004;**52**:712-8.
10. Chiarelli PE, Mackenzie LA, Osmotherly PG. Urinary incontinence is associated with an increase in falls: a systematic review. *Aust J Physiother* 2009;**55**:89-95.
11. Holroyd-Leduc JM, Tannenbaum C, Thorpe KE, Straus SE. What type of urinary incontinence does this woman have? *JAMA* 2008;**299**:1446-56.
12. Goode PS, Burgio KL, Richter HE, Markland AD. Incontinence in older women. *JAMA* 2010;**303**:2172-81.

13. Tannenbaum C, Bachand, G, DuBeau CE, Kuchel GA. Experience of an incontinence clinic for older women : no apparent age limit for potential physical and psychological benefits. *J Women Health Gend Based Med* 2001;**10**:751-56.
14. Tannenbaum C, Brouillette J, Corcos J. Rating improvements in urinary incontinence: do patients and physicians agree? *Age Ageing* 2008;**37**:1-5
15. Newman DK, Buckley B, Gordon D et al. Continence promotion, education and primary prevention. In Abrams P, Cardozo L, Khoury S, Wein A eds: *Incontinence*. 5<sup>th</sup> International Consultation on Incontinence, Paris, February 2012. Health Publication Ltd 2013.
16. Agnew R, van den Heuvel E, Tannenbaum C. Efficiency of using community organisations as catalysts for recruitment to continence promotion trials. *Clin Trials* 2013;**10**:151-9.
17. Tannenbaum C, Drali R, Holroyd-Leduc J Richard L. Lessons learned: Impact of a continence promotion activity for older community dwelling women. *Neurourol Urodyn* 2010;**29**:540-544.
18. Wilde MH, Bliss DZ, Booth J, Cheater F, Tannenbaum C. Self-Management of Urinary and Fecal Incontinence. *AJN* 2013 in press.
19. Holroyd-Leduc J, Strauss S, Thorpe K, Davis D, Schmaltz H, Tannenbaum C. Translation of evidence into a self-management tool for use by women with urinary incontinence. *Age Ageing* 2011;**40**:227-33.
20. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. *Am J Obstet Gynecol* 2003;**189**: 98–101.
21. Avery K, Donovan J, Peters TJ et al. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. *Neurourol Urodyn* 2004; **23**: 322–30.
22. Eldridge SM; Ashby D; Kerry S. Sample size for cluster randomised trials: effect of coefficient of variation of cluster size and analysis method. *Int J Epidemiol* 2006;**35**:1292-1300.
23. Ukoumunne OC, Forbes AB, Carlin JB, Gulliford MC. Comparison of the risk difference, risk ratio and odds ratio scales for quantifying the unadjusted intervention effect in cluster randomised trials. *Stat Med* 2008;**27**: 5143-5155.
24. Users' guide to the medical literature. Integrating research evidence with the care of the individual patient. *JAMA* 2000;**283**:2829-2836.

25. Hanley JA, Negassa A, Edwardes MD. GEE analysis of negatively correlated binary responses: a caution. *Stat Med* 2000;**19**:715–722.
26. Craig P, Dieppe P, Macintyre S, Mitchie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;**337**:979-983.
27. Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement: extension to cluster randomised trials. *BMJ* 2012;**345**:e5661.
28. Kincade JE, Dougherty MC, Carlson JR, Hunter GS, Busby-Whitehead J. Randomised clinical trial of efficacy of self-monitoring techniques to treat urinary incontinence in women. *Neurourol Urodyn* 2007;**26**:507-11.
29. Wagg AR, Barron D, Kirby M, Stott D, Corlett K. A randomised partially controlled trial to assess the impact of self-help vs. structured help from a continence nurse specialist in women with undiagnosed urinary problems in primary care. *Int J Clin Pract* 2007;**61**:1863-73.
30. Dougherty MC, Dwyer JW, Pendergast JF et al. A randomised trial of behavioral management for continence with older rural women. *Res Nurs Health* 2002;**25**:3-13.
31. McFall SL, Yerkes AM, Cowan LD. Outcomes of a small group educational intervention for urinary incontinence: episodes of incontinence and other urinary symptoms. *J Aging Health* 2000;**12**:250-67.
32. Milne J. The impact of information on health behaviors of older adults with urinary incontinence. *Clin Nurs Res* 2000;**9**:161-76.
33. Goode PS, Burgio KL, Locher JL et al. Effect of behavioral training with or without pelvic floor electrical stimulation on stress incontinence in women: a randomized controlled trial. *JAMA* 2003;**290**(3):345-52.
34. Shamliyan T, Wyman J, Kane RL. Nonsurgical treatments for urinary incontinence in adult women: diagnosis and comparative effectiveness. Comparative Effectiveness Review No. 36. (Prepared by the University of Minnesota Evidence-based Practice Center under Contract No. HHSA 290-2007-10064-I.) AHRQ Publication No. 11(12)-EHC074-EF. Rockville, MD. Agency for Healthcare Research and Quality. April 2012. Available at: [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm).

Table 1: Baseline characteristics and distribution of modifiable risk factors of participants

	Continence education (n=64)	Self-management (n=70)	Combined intervention (n=61)	Control intervention (n=64)
	<b>Mean ± SD</b>			
Age	70.8 ± 7.9	71.0 ± 6.8	70.4 ± 6.7	74.1 ± 8.1
Mean ICIQ score*	8.5 ± 4.4	6.8 ± 3	7.3 ± 5.6	6.7 ± 3.4
	<b>(% yes)</b>			
Lives alone	48.4	40.0	37.7	59.4
Education				
University degree or equivalent	31.2	45.7	37.7	19.0
General health perception				
Good, very good, excellent	53.1	85.7	80.3	75.0
Fair/poor	45.3	14.3	16.4	25.0
Depression	48.4	35.7	32.8	20.3
Heart disease	35.9	25.7	16.4	21.0
Falls	45.3	31.4	18.0	18.8
Arthritis	78.1	52.9	44.3	57.8
Diabetes	39.1	24.3	18.0	20.3
High blood pressure	59.0	40.0	45.9	55.6
<b>Type of incontinence</b>				
Stress only	15.6	12.9	14.8	33.3
Urgency only	32.8	35.7	29.5	20.6
Mixed	45.3	42.9	55.7	39.7
<b>Modifiable risk factors</b>				
Performs pelvic floor muscle exercises 3 times per week	18.8	15.7	11.9	15.6
Self-reported body mass index $\geq 27$ kg/m <sup>2</sup> **	53.2	53.0	42.4	49.2
Drinks more than 1.5 litres of fluid/day	43.8	44.3	54.1	37.5
Drinks one cup of tea or more/day	85.9	84.3	73.8	84.4
Drinks one cup of coffee or more/day	46.9	62.9	65.6	64.1
Smokes	6.3	4.3	4.9	6.2

\*ICIQ = International Consultation on Incontinence Questionnaire, used to measure the severity and bother from urinary incontinence. Scores range from 0 to 21, with higher scores representing worse incontinence.

1  
2  
3  
4 \*\*Self-reported body mass index: calculated as weight (kg)/height<sup>2</sup> (m) based on  
5 participant's self-reported height and weight at baseline  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 2: Prevalence, risk difference and odds ratios for self-reported improvements in incontinence at 3-months

	Prevalence at 3-month follow-up				Prevalence difference (95% CI)*			Odds ratio (95% CI)					
	Conti- nence	SM	Combined	Control	Conti- nence vs control	SM vs control	Combined vs control	Crude			Adjusted**		
								Conti- nence vs control	SM vs control	Combined vs control	Conti- nence vs control	SM vs control	Combined vs control
<b>Any improvement</b>													
Intention-to- treat	0.59	0.41	0.66	0.11	0.48 (0.33-0.64)	0.28 (0.08- 0.48)	.55 (0.43- 0.67)	11.72 (4.54- 30.21)	5.16 (1.73- 15.37)	15.51 (6.50- 37.01)	9.14 (3.05- 27.37)	2.71 (0.87- 8.41)	17.63 (5.09- 61.13)
Per protocol	0.64	0.47	0.73	0.13	0.51 (0.34- 0.67)	0.29 (0.07- 0.51)	0.59 (0.45- 0.74)	11.45 (4.27- 30.67)	4.64 (1.48- 14.56)	17.14 (6.51- 45.11)	10.40 (3.05- 35.48)	3.46 (1.08- 11.03)	23.27 (5.91- 91.59)
ICC Intention-to- treat	-	-	-	-	0.02	0.18	0	0.24	0.18	0	0	0.06	0
ICC per protocol	-	-	-	-	0.03	0.25	0	0.03	0.25	0	0	0.14	0
<b>Very much better or much better</b>													
Intention-to- treat	0.22	0.21	0.30	0.06	0.16 (0.03- 0.29)	0.14 (0.01- 0.27)	0.23 (0.10- 0.36)	4.2 (1.4-13.0)	3.8 (1.2-12.2)	6.3 (2.2- 17.7)	2.83 (0.59- 13.66)	1.81 (0.50- 6.60)	4.94 (1.45- 16.86)



Per protocol	0.24	0.24	0.33	0.08	0.16 (0.02-0.30)	0.15 (0.00-0.29)	0.26 (0.10-0.42)	3.7 (1.2-11.3)	3.5 (1.06-11.31)	5.8 (2.0-17.4)	2.51 (0.48-13.18)	2.28 (0.63-8.24)	5.32 (1.39-20.34)
ICC Intention-to-treat	-	-	-	-	0.02	0.06	0	0.02	0.06	0	0	0	0
ICC per protocol	-	-	-	-	0.01	0.08	0.02	0.01	0.08	0	0	0.02	0

SM = Self-management; ICC = intra-cluster correlation correlation

\*95% CI's were calculated using robust standard errors

\*\*Adjusted for age, living alone, depression, heart disease, falls, arthritis, diabetes, high blood pressure, educational status, general health perception, and baseline incontinence severity score

Table 3: Change in incontinence-related knowledge

		Continence education n=64	Self-management n=70	Combined intervention n=61	Control n=64
1. Urinary incontinence is a normal part of ageing	Baseline % agreement	73.0	79.7	77.0	79.7
	3 month follow up % agreement	36.2	63.9	38.2	82.7
	p value for change*	<b>&lt;0.001</b>	<b>0.02</b>	<b>&lt;0.001</b>	0.73
2. Once people start to leak urine, they are never able to control their urine again	Baseline % agreement	41.9	32.9	36.1	50.8
	3 month follow up % agreement	29.3	17.7	7.3	51.9
	p value for change	0.12	0.06	<b>&lt;0.001</b>	1
3. Urine leakage can be caused by many different things	Baseline % agreement	88.9	92.8	88.3	86.9
	3 month follow up % agreement	93.1	88.7	92.7	90.4
	p value for change	1	0.77	0.73	0.63
4. Wearing pads or diapers is the best way to manage urinary incontinence	Baseline % agreement	57.1	40.6	52.5	67.2
	3 month follow up % agreement	36.8	33.9	27.3	69.2
	p value for change	<b>0.03</b>	0.11	<b>0.001</b>	1
5. What you drink can contribute to urine leakage	Baseline % agreement	64.5	66.7	68.3	66.1
	3 month follow up % agreement	77.6	75.8	89.1	68.6

		Continence education n=64	Self-management n=70	Combined intervention n=61	Control n=64
	p value for change	0.26	0.36	<b>0.01</b>	0.77
6. How much you drink can contribute to urine leakage	Baseline % agreement	72.6	65.2	67.2	71.4
	3 month follow up % agreement	77.6	71	76.4	65.4
	p value for change	0.63	0.65	0.36	0.79
7. Losing weight can lead to improvement in incontinence	Baseline % agreement	61.3	74.3	66.1	75
	3 month follow up % agreement	77.6	77.4	90.9	80.8
	p value for change	0.08	0.69	<b>&lt;0.001</b>	0.48
8. Exercising pelvic floor muscles can help control urine leakage	Baseline % agreement	85.5	88.6	85.2	96.9
	3 month follow up % agreement	96.5	96.7	98.2	98.1
	p value for change	<b>0.04</b>	0.13	<b>0.02</b>	1.0

\* McNemar's test for matched-pairs data

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1: Flow of participants through the trial





Figure 1: Flow of participants through the trial  
235x186mm (300 x 300 DPI)

Figure 2: Change in risk-modifying behaviours at 3-month follow-up



\*Significantly different from the control group ( $p < 0.05$ ) using Fisher's Exact test in per protocol analysis  
 Error bars represent 95% confidence intervals

Figure 2: Change in risk-modifying behaviours at 3-month follow-up  
 297x186mm (300 x 300 DPI)

Review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1: CONSORT 2010 checklist of information to include when reporting a cluster randomised trial**

Section/Topic	Item No	Standard Checklist item	Extension for cluster designs	Page No *
<b>Title and abstract</b>				
	1a	Identification as a randomised trial in the title	Identification as a cluster randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) <sup>1,2</sup>	See table 2	3-4
<b>Introduction</b>				
<b>Background and objectives</b>	2a	Scientific background and explanation of rationale	Rationale for using a cluster design	6
	2b	Specific objectives or hypotheses	Whether objectives pertain to the cluster level, the individual participant level or both	5
<b>Methods</b>				
<b>Trial design</b>	3a	Description of trial design (such as parallel, factorial) including allocation ratio	Definition of cluster and description of how the design features apply to the clusters	6
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons		-
<b>Participants</b>	4a	Eligibility criteria for participants	Eligibility criteria for clusters	6-7
	4b	Settings and locations where the data were collected		6
<b>Interventions</b>	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	Whether interventions pertain to the cluster level, the individual participant level or both	7
<b>Outcomes</b>	6a	Completely defined pre-specified primary and secondary outcome measures, including how and	Whether outcome measures pertain to the cluster level, the individual participant level or both	8

		when they were assessed		
	6b	Any changes to trial outcomes after the trial commenced, with reasons		-
<b>Sample size</b>	7a	How sample size was determined	Method of calculation, number of clusters(s) (and whether equal or unequal cluster sizes are assumed), cluster size, a coefficient of intracluster correlation (ICC or <i>k</i> ), and an indication of its uncertainty	9,26
	7b	When applicable, explanation of any interim analyses and stopping guidelines		-
<b>Randomisation:</b>				
<b>Sequence generation</b>	8a	Method used to generate the random allocation sequence		8
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	Details of stratification or matching if used	8
<b>Allocation concealment mechanism</b>	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	Specification that allocation was based on clusters rather than individuals and whether allocation concealment (if any) was at the cluster level, the individual participant level or both	8
<b>Implementation</b>	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	Replace by 10a, 10b and 10c	-
	10a		Who generated the random allocation sequence, who enrolled clusters, and who assigned clusters to interventions	8
	10b		Mechanism by which individual participants were included in clusters for the purposes of the trial (such as complete	6

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

			enumeration, random sampling)	
	10c		From whom consent was sought (representatives of the cluster, or individual cluster members, or both), and whether consent was sought before or after randomisation	6
<b>Blinding</b>	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how		8
	11b	If relevant, description of the similarity of interventions		8
<b>Statistical methods</b>	12a	Statistical methods used to compare groups for primary and secondary outcomes	How clustering was taken into account	9-10
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses		9-10
<b>Results</b>				
<b>Participant flow (a diagram is strongly recommended)</b>	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	For each group, the numbers of clusters that were randomly assigned, received intended treatment, and were analysed for the primary outcome	26
	13b	For each group, losses and exclusions after randomisation, together with reasons	For each group, losses and exclusions for both clusters and individual cluster members	26
<b>Recruitment</b>	14a	Dates defining the periods of recruitment and follow-up		6
	14b	Why the trial ended or was stopped		-
<b>Baseline data</b>	15	A table showing baseline demographic and clinical	Baseline characteristics for the individual and cluster levels as	20



		characteristics for each group	applicable for each group	
<b>Numbers analysed</b>	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	For each group, number of clusters included in each analysis	26
<b>Outcomes and estimation</b>	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	Results at the individual or cluster level as applicable and a coefficient of intracluster correlation (ICC or $k$ ) for each primary outcome	11,22-25
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended		11,22-25
<b>Ancillary analyses</b>	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory		11,22-25
<b>Harms</b>	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms <sup>3</sup> )		-
<b>Discussion</b>				
<b>Limitations</b>	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses		12
<b>Generalisability</b>	21	Generalisability (external validity, applicability) of the trial findings	Generalisability to clusters and/or individual participants (as relevant)	13-14
<b>Interpretation</b>	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence		13-14
<b>Other information</b>				
<b>Registration</b>	23	Registration number and		4

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

		name of trial registry	
<b>Protocol</b>	24	Where the full trial protocol can be accessed, if available	-
<b>Funding</b>	25	Sources of funding and other support (such as supply of drugs), role of funders	4,16

\* Note: page numbers optional depending on journal requirements

For peer review only

**Table 2: Extension of CONSORT for abstracts<sup>1,2</sup> to reports of cluster randomised trials**

Item	Standard Checklist item	Extension for cluster trials
<b>Title</b>	Identification of study as randomised	<b>Identification of study as cluster randomised</b>
<b>Trial design</b>	Description of the trial design (e.g. parallel, cluster, non-inferiority)	
<b>Methods</b>		
<b>Participants</b>	Eligibility criteria for participants and the settings where the data were collected	<b>Eligibility criteria for clusters</b>
<b>Interventions</b>	Interventions intended for each group	
<b>Objective</b>	Specific objective or hypothesis	<b>Whether objective or hypothesis pertains to the cluster level, the individual participant level or both</b>
<b>Outcome</b>	Clearly defined primary outcome for this report	<b>Whether the primary outcome pertains to the cluster level, the individual participant level or both</b>
<b>Randomization</b>	How participants were allocated to interventions	<b>How clusters were allocated to interventions</b>
<b>Blinding (masking)</b>	Whether or not participants, care givers, and those assessing the outcomes were blinded to group assignment	
<b>Results</b>		
<b>Numbers randomized</b>	Number of participants randomized to each group	<b>Number of clusters randomized to each group</b>
Recruitment	Trial status <sup>1</sup>	
<b>Numbers analysed</b>	Number of participants analysed in each group	<b>Number of clusters analysed in each group</b>
<b>Outcome</b>	For the primary outcome, a result for each group and the estimated effect size and its precision	<b>Results at the cluster or individual participant level as applicable for each primary outcome</b>
<b>Harms</b>	Important adverse events or side effects	
<b>Conclusions</b>	General interpretation of the results	
<b>Trial registration</b>	Registration number and name of trial register	
<b>Funding</b>	Source of funding	

<sup>1</sup> Relevant to Conference Abstracts

## REFERENCES

- 1 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomised trials in journal and conference abstracts. *Lancet* 2008, 371:281-283
- 2 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG at al (2008) CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. *PLoS Med* 5(1): e20
- 3 Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D. Better reporting of harms in randomized trials: an extension of the CONSORT statement. *Ann Intern Med* 2004; 141(10):781-788.